Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Molecular analysis of cerebrospinal fluid in viral diseases of the central nervous system

Paola Cinque a,⁎, Simona Bossolasco a, Åke Lundkvist b

a Clinic of Infectious Diseases, San Raffaele Hospital, Via Stamira d’Ancona, 20, Milan 20127, Italy
b Department of Virology, Swedish Institute for Infectious Diseases Control and Microbiology and Tumorbiology Center, Karolinska Institute 17182 Solna, Sweden

Accepted 12 September 2002

Abstract

The use of nucleic acid (NA) amplification techniques has transformed the diagnosis of viral infections of the central nervous system (CNS). Because of their enhanced sensitivity, these methods enable detection of even low amounts of viral genomes in cerebrospinal fluid. Following more than 10 years of experience, the polymerase chain reaction or other NA-based amplification techniques are nowadays performed in most diagnostic laboratories and have become the test of choice for the diagnosis of several viral CNS infections, such as herpes encephalitis, enterovirus meningitis and other viral infections occurring in human immunodeficiency virus-infected persons. Furthermore, they have been useful to establish a viral etiology in neurological syndromes of dubious origin and to recognise unusual or poorly characterised CNS diseases. Quantitative methods have provided a valuable additional tool for clinical management of these diseases, whereas post-amplification techniques have enabled precise genome characterisation. Current efforts are aiming at further improvement of the diagnostic efficiency of molecular techniques, their speed and standardisation, and to reduce the costs. The most relevant NA amplification strategies and clinical applications of to date will be the object of this review.

© 2002 Elsevier Science B.V. All rights reserved.

Keywords: Nucleic acid amplification; Central nervous system; Cerebrospinal fluid; Polymerase chain reaction

1. Introduction

Cerebrospinal fluid (CSF) examination is an essential part of the diagnostic work-up of patients with suspected central nervous system (CNS) viral infections. It is often the means to achieve an etiological diagnosis, either by the direct identification of the responsible virus, or by the demonstration of an intrathecal specific immune response. Traditional direct virological techniques, including virus isolation, antigen detection and microscopy examination, usually have low sensitivity. Only virus isolation in cell culture may be of some value for diagnosis of aseptic meningitis, with enteroviruses found in almost half of the cases. Virus isolation, however, is insensitive for
other viruses, such as herpes simplex virus type 1 (HSV-1) and most arboviruses. Virus antigen detection techniques and light or electron microscopy are of limited value, as they require a high number of CSF-infected cells for virus identification (Rubin, 1983). On the other hand, indirect diagnosis by detection of intrathecally produced antibodies generally has poor sensitivity during the early stages of the disease.

Over the last decade, nucleic acid (NA) amplification-based techniques, primarily the polymerase chain reaction (PCR), have revolutionised the diagnosis of CNS infections, especially those caused by viruses (Fredricks and Relman, 1999). Their advantages, accounting for their success in diagnostic neurovirology, have been the extraordinary sensitivity and rapidity. These techniques were first applied to CSF in the early 90s, for the diagnosis of herpes simplex encephalitis (HSE), and enteroviral meningitis (Puchhammer-Stöckl et al., 1990; Rotbart, 1990). Since then, the number of scientific reports in this field has rapidly increased and NA amplification-based assays are now routinely performed in most diagnostic laboratories.

NA amplification-based techniques have become the test of choice for some viral CNS infections, such as HSE (Darnell, 1993; Tyler, 1994; Weber et al., 1996; Cinque et al., 1996a). Furthermore, they have been useful to establish a viral etiology in neurological syndromes of dubious origin, e.g., Mollaret’s meningitis (Tedder et al., 1994), or to help recognise unusual or poorly characterised CNS diseases, such as mild forms of herpes encephalitis (Schlesinger et al., 1995a; DeVincenzo and Thorne, 1994; Domingues et al., 1997; Fodor et al., 1998) or cytomegalovirus (CMV) ventriculoencephalitis in human immunodeficiency virus (HIV)-infected patients (Arribas et al., 1996). Molecular methods have made it possible to identify viruses in CSF normally causing extracerebral infections, such as rotavirus, parvovirus B19, CMV or human herpesvirus 6 (HHV-6), thus supporting their etiological role in inducing CNS disease (Kondo et al., 1993; Suga et al., 1993; Cassinotti et al., 1993; Ushijima et al., 1994; Studahl et al., 1995; McCullers et al., 1995; Barah et al., 2001). Finally, molecular techniques have been of unique value for identification of novel viruses responsible of CNS disease (Chua et al., 2000; Cardosa et al., 1999).

2. Nucleic acid amplification

2.1. Methods

2.1.1. CSF preparation

CSF treatment is usually required prior to NA amplification, in order to release NA from cells and to remove substances that may degrade NA or inhibit amplification. However, the relatively simple CSF composition may obviate, at least for DNA viruses, the need for NA purification. The simplest approaches include heating to high temperatures or repeated freeze-thawing of the specimens, procedures that facilitate cell membrane disruption and release of DNA (Table 1). These procedures have the advantage of being rapid, requiring small CSF volumes, and reducing the risk of sample contamination during NA purification steps. However, the lack of removal of inhibiting molecules might interfere with the

| Principle                   | Method (examples)                                         |
|-----------------------------|-----------------------------------------------------------|
| CSF cell lysis              | Heating to 95 °C, freezing thawing Detergents (SDS), proteases (protease K), chaotropioc agents (guanidinium thiocyanate) |
| CSF cell lysis-protein digestion | Ultracentrifugation Ethanol precipitation of nucleic acids |
| Nucliec acid concentration  | Phenol–chloroform, spin column, silicate absorption, magnetic separation |
| Nuclide acid extraction     |                                                           |

Methods for cell lysis, and concentration and extraction of nucleic acids can variably be combined. Required time varies from 10 min (e.g., by mechanical cell lysis) to ≥ 1 h (e.g., protease K digestion and/or complex nucleic acid procedures, e.g., phenol–chloroform). Required volume varies from 2-5 μl (e.g., mechanical cell lysis) to ≥ 1 ml (use of CSF concentration procedures).
enzymes used for amplification. NAs may also be concentrated and/or purified from CSF, by a number of in-house procedures or commercial kits (Table 1). Although some extraction methods seem to perform better than others in comparative studies (Casas et al., 1995; Fahle and Fischer, 2000), none of the known protocols has been shown to be clearly superior. Practically, the choice of one CSF preparation method is supported by a number of considerations, including the type of NA target and the amplification protocol employed, as well as the individual laboratory experience.

2.1.2. NA amplification techniques

NA amplification techniques enable the amplification of small quantities of target NA molecules to considerably larger amounts (over $10^6$ copies), which can be visualised by means of common laboratory procedures. This results in a very high sensitivity, which is the main advantage of these techniques. PCR is the most popular amplification method, but a number of other techniques have been described, including the ligase chain reaction, the strand displacement assay, the transcription mediated amplification, the nucleic acid sequence based amplification (NASBA), the branched DNA technique, and the hybrid capture assay (Tang and Persing, 1999).

PCR has been widely used for detection in CSF of both DNA and RNA viruses. In the case of RNA viruses, a complementary DNA (cDNA) needs to be generated from RNA prior to amplification, by means of a reverse transcriptase (RT). A variant of the classical procedure, largely used for analysis of CSF and other biological fluids containing few viral particles, is the ‘nested’ PCR. This consists of two separate amplification reactions using two primer sets, the second of which is located between the first one, thus increasing substantially both sensitivity and specificity of detection (Tang and Persing, 1999).

NA amplification techniques other than PCR that have been applied to detect viral genomes in CSF include the NASBA and the branched DNA assays. NASBA, like PCR, is based on target NA amplification, but the synthesis of new molecules occurs through an isothermal reaction and requires three different enzymes. Furthermore, the template consists of RNA (Kievišs et al., 1991). Examples of NASBA studies of CSF include those performed to detect the CMV pp67 late gene transcripts in HIV-infected patients with CMV encephalitis; enterovirus, West Nile (WN) or St. Louis encephalitis virus RNA in patients with aseptic meningitis or encephalitis (Zhang et al., 2000; Bestetti et al., 2001; Lanciotti and Kerst, 2001; Heim and Schumann, 2002; Fox et al., 2002), and to assess HIV-1 RNA levels in patients with HIV infection at different disease stages (McArthur et al., 1997; Shepard et al., 2000). The branched DNA assay is based on signal amplification rather than target-amplification (Urdea, 1994). This assay has been used to measure CMV DNA and HIV-1 RNA levels in the CSF of HIV-infected patients (Flood et al., 1997; Stingele et al., 2001).

2.1.3. Detection of amplified products

There are different procedures to detect the products of NA amplification. The simplest technique is based on the visualisation of DNA bands of the expected size by agarose gel electrophoresis after staining with ethidium-bromide. Alternative or supportive methods include hybridisation with DNA probes complementary to the target DNA, following DNA transfer to a filter, tubes, or microplates. Probes are labelled with enzymes or other molecules that lead to signal detection on appropriate stimulation. Colorimetric enzyme-linked immunosorbent assays (ELISA), in which the amplified products is captured by a probe coated to a microplate, have proved to be very practical. For this reason colorimetric ELISAs have largely been adapted to commercial kits and used for CSF analysis for a number of viruses (Rotbart et al., 1994; Ellis et al., 1997; Bestetti et al., 2001).

2.1.4. Variants of PCR. Multiplex PCR and PCR with consensus primers

Since similar neurological pictures may result from different CNS infections, it may be practical to use PCR assays that detect more than one virus or infectious agent in the same reaction. The most obvious advantage of this approach is that the
number of tests are reduced, with substantial time and cost savings. Two main strategies are used for this purpose: multiplex PCR and PCR with consensus primers.

Multiplex PCR enables the identification of more than one DNA sequence by means of two or more primer pairs, each specific for one sequence (Fig. 1). An important requirement of this approach is that the amplification conditions, i.e. reagent mixture composition and thermocycling profile, are similar for all the primer pairs, in order not to compromise amplification efficiency for each primer pair. Developments of multiplex PCR might lead to universal diagnostic protocols, based on the use of several primer pairs with fixed thermocycle programs and reagent composition (Kuno, 1998). Multiplex PCR assays are largely employed in diagnostic neurovirology, e.g. for simultaneous detection of HSV-1 and HSV-2 (Kimura et al., 1990; Cassinotti et al., 1996; Cinque et al., 1998a), or of a larger number of herpesviruses (Tenorio et al., 1993; Baron et al., 1996; Pozo and Tenorio, 1999; Quereda et al., 2000; Markoulatos et al., 2001). Protocols have also been designed for simultaneous amplification of viruses causing similar clinical pictures. These include assays for herpesvirus and enterovirus (Read and Kurtz, 1999; Casas et al., 1999), for measles, rubella and parvovirus B19 (del Mar Mosquera et al., 2002) or for different combinations of mosquito-transmitted viruses (Lee et al., 2002). A duplex PCR protocol for the amplification of Epstein–Barr virus (EBV) and Toxoplasma gondii has also been proposed in AIDS patients to help distinguish CNS lymphoma from toxoplasmosis (Roberts and Storch, 1997).

PCR with consensus primers is used to amplify conserved sequences in common to different viruses, but belonging to the same family. Following amplification, the product may be identified by DNA sequencing, by hybridisation with specific probes or by restriction-enzyme analysis (Fig. 2), or, when possible, by visualisation of bands of different size on agarose gel. This strategy has widely and successfully been used with herpesviruses: to amplify simultaneously HSV-1, HSV-2, CMV and EBV by means of primers targeting conserved region of the herpesvirus DNA polymerase gene (Rozenberg and Lebon, 1991), to detect all the known human herpesviruses in two PCR assays (Johnson et al., 2000) or most of them in a single reaction through the use of ‘stair primers’ (Minjolle et al., 1999; Bouquillon et al., 2000). Further examples include protocols designed to detect most enterovirus strains using primers that recognise conserved sequences within the 5’ non-coding region of the picornavirus family (Kammerer et al., 1994), the three human polyomaviruses JC virus (JCV), BK virus and SV40 (Arthur et al., 1989; Fedele et al., 1999) or different flaviviruses (Harris et al., 1998; Scaramozzino et al., 2001; Mousavi-Jazi and Lundkvist, unpublished observation).

Fig. 1. Example of multiplex PCR. Three unrelated sequences of HSV-1, HSV-2 and VZV, are amplified simultaneously in the same test tube by using three different primer pairs, specific for each virus. The amplification products can be differentiated on agarose gel if the amplified fragments yield bands of different size (M: 100 bp DNA ladder marker). Alternatively, amplification products can be identified through an additional step, by hybridization with specific probes, restrictions enzyme analysis, nested PCR with specific internal primers, or DNA sequencing.
2.1.5. False positive and false negative results

The possibility of generating false positive results by sample contamination is a major risk of NA amplification techniques. Clinical specimens or products of previous amplifications (carry-over) are the most common source of contamination. In order to minimize this risk, it is recommended to maintain CSF sterility in all the pre-laboratory and laboratory steps and to carry out the different laboratory steps in separate areas (Persing, 1991). In addition, some laboratories use the enzyme uracil N-glycosilase (UNG), which degrades products from previous amplifications but not native NA templates, to prevent carry-over of amplification products. This is accomplished by substituting dUTP for dTTP in the amplification mixture, and pretreating all subsequent mixtures with UNG prior to amplification (Longo et al., 1990). More in general, the use of negative controls, usually water or known negative samples tested in parallel with the CSF specimens throughout the whole procedure, and analysis of samples in duplicate, are useful to recognize false positive results.

False negative results can be caused by the presence of inhibitors, i.e. molecules affecting the correct functioning of enzymes. Inhibition of amplification has been reported in 1–5% of CSF specimens (Tang et al., 1999). In order to reveal the presence of inhibition, it may be useful to amplify ‘internal standard’ molecules together with the target. In addition, amplification of

---

Fig. 2. Example of PCR assay with consensus primers (adapted from Rozenberg and Lebon, 1991). Conserved DNA sequence from the polymerase genes of HSV-1, HSV-2, EBV and CMV are amplified simultaneously in the same tube by a consensus primer pair targeting regions in common to these viruses. Following agarose gel electrophoresis, the amplified products have similar length (top) but each virus can be distinguished by using restriction enzymes (bottom) (a, SmaI and b, BamHI; M: DNA marker). Alternatively, viruses can be differentiated following hybridization with virus-specific probes or DNA sequencing.
both strong and weak positive controls in parallel with CSF samples can further help monitoring amplification efficiency of the whole reaction.

2.1.6. CSF storage conditions

Since viable virus is not necessary for NA amplification-based procedures, NAs can be found in CSF samples kept stored for long periods. DNA of HSV can be recovered in CSF samples maintained for up to 30 days at $-20\ ^\circ \mathrm{C}$, 2–8 $^\circ \mathrm{C}$, and even at room temperature (Wiedbrauk and Cunningham, 1996). Actually, it has been recovered following storage at $-20\ ^\circ \mathrm{C}$ for several years (personal observation). From a practical point of view, it is considered safe to send CSF specimens for the search of DNA viruses to the laboratory at room temperature. However, it is preferable that CSF samples are kept at 4 $^\circ \mathrm{C}$ even for short-term storage, or frozen if they cannot be delivered or examined within 1 day (Cinque et al., 1996a).

On the other hand, RNA is regarded to be less stable than DNA, and its detection in plasma seems to be affected by factors such as, the type of anticoagulant used for specimen collection and storage temperature (Moudgil and Daar, 1993; Holodniy et al., 1995). However, recovery of enterovirus RNA in CSF seems not to be reduced by storage at 4 $^\circ \mathrm{C}$ or room temperature for 96 h after sampling (Rotbart et al., 1985). Similarly, no significant decay of HIV-1 RNA load was observed after up to 96 h of storage at 4 $^\circ \mathrm{C}$ (Ahmad et al., 1999). Theoretically, storage at 4 $^\circ \mathrm{C}$ might actually be advantageous in the case of enveloped RNA viruses, because freezing may destroy the envelope, and thus make the RNA vulnerable to nucleases.

2.2. Clinical applications

Tables 2 and 3 show an overview of NA amplification use in diagnostics, in immunocompetent and immunocompromised patients, respectively. Some of the most relevant examples will be briefly emphasised.

2.2.1. Herpes simplex encephalitis

The detection of HSV-1 DNA in CSF is one of the most convincing examples of the diagnostic use of molecular analysis. This approach has now largely replaced the identification of HSV in brain tissue biopsies as the method of choice for the etiological diagnosis of HSE (Linde et al., 1997; Tang et al., 1999). A number of retrospective and prospective studies have demonstrated the reliability of PCR methods, reporting a sensitivity higher than 90% and a virtually 100% specificity (Aurelius et al., 1991; Lakeman and Whitley, 1995; Linde et al., 1997). Furthermore, NA amplification techniques enable the diagnosis of uncommon forms of HSV CNS infection that might otherwise go unrecognised (Schlesinger et al., 1995b; DeVincenzo and Thorne, 1994; Domingues et al., 1997; Fodor et al., 1998). Most importantly, CSF analysis by these techniques is rapid, making the laboratory diagnosis useful for management decisions. However, it is important that the PCR results are interpreted cautiously in relation to the clinical presentation and the duration of antiviral therapy. Initially negative PCR results have been observed very early after onset of HSE symptoms, likely to reflect a still limited virus replication (Rozenberg and Lebon, 1991; Puchhammer-Stöckl et al., 2001). On the other hand, the likelihood of finding a positive CSF PCR result is reduced following a few days of acyclovir treatment, as well as in untreated patients from whom CSF is obtained late after onset of neurological symptoms (Rozenberg and Lebon, 1991; Aurelius et al., 1991; Lakeman and Whitley, 1995).

2.2.2. Enterovirus meningitis

Although enteroviruses are frequently isolated from CSF of patients with enteroviral meningitis by cell culture, molecular techniques have significantly improved the detection rate of these infections (Jeffery et al., 1997). Protocols have been designed with primers that recognise almost all of the enterovirus serotypes, including those that can not be isolated in cell systems. Exceptions are Echo viruses 22 and 23 that diverge extremely from the other serotypes (Oberste et al., 1998). Because of the enhanced sensitivity of NA amplification methods, the virus can also be detected in CSF samples obtained a few days after onset of symptoms, where isolation of virus is usually infrequent (Yerly et al., 1996). Furthermore, the
| Family (nucleic acid) | Virus | Main Common Clinical Syndromes | Significance of NA detection in CSF^{b} | Comments | References |
|----------------------|-------|---------------------------------|--------------------------------------|----------|------------|
| Herpesviridae (dsDNA) | HSV-1 | Herpes encephalitis (HSE), neonatal infection | Diagnosis of HSE (test of choice), etiological characterization and diagnosis of atypical HSE forms, diagnostic potential in neonatal infections | > 90% sensitivity vs. brain biopsy | Aurelius et al. (1991), Kimura et al. (1991), Lakeman and Whitley (1995), Linde et al. (1997), Kimberlin et al. (1996) |
| | HSV-2 | Aseptic meningitis, recurrent meningitis, neonatal infection | Diagnosis of aseptic meningitis, etiological characterization and diagnosis of recurrent meningitis, diagnostic potential in neonatal infections | Kimura et al. (1991), Aurelius et al. (1993), Tedder et al. (1994), Schlesinger et al. (1995b), Kimberlin et al. (1996) |
| | VZV | Varicella and herpes zoster (HZ) complications | Diagnosis of aseptic meningitis and others VZV-associated CNS diseases | NA detection also in cases of uncomplicated HZ | Puchhammer-Stöckl et al. (1991), Echevarria et al. (1994), Haampaa et al. (1998) |
| | CMV | Aseptic meningitis, encephalitis, neonatal infection | Etiological characterization and diagnosis of various neurological syndromes, diagnostic potential in neonatal infections | Darin et al. (1994), Troendle Atkins et al. (1994), Studahl et al. (1995) |
| | EBV | Aseptic meningitis, encephalitis | Association with febrile child seizures and encephalitis | Imai et al. (1993), Landgren et al. (1994), Kondo et al. (1993), Suga et al. (1993), Caserta et al. (1994), McCullers et al. (1995), Hall et al. (1998) |
| | HHV-6 | Febrile seizures, encephalitis | Association with febrile child seizures and other neurological conditions | Torigoe et al. (1996), van den Berg et al. (1999), Yoshikawa et al. (2000), Komatsu et al. (2000), Pohl-Koppe et al. (2001) |
| | HHV-7 | Febrile seizures | Association with febrile child seizures and other neurological conditions | Voltz et al. (1996) |
| Polyomaviridae (ssDNA) | BKV | Encephalitis? | Occasional association with encephalitis | Keidan et al. (1992), Nishimura et al. (1993), Ushijima et al. (1994), Abe et al. (2000) |
| Reoviridae (ssDNA) | Rotavirus | Aseptic meningitis, encephalitis | Etiological characterization and diagnosis of rotavirus CNS diseases | Cassinotti et al. (1993), Okumura and Ichikawa (1993), Druschky et al. (2000), Barah et al. (2001) |
| Parvoviridae (ssDNA) | Parovirus B19 | Aseptic meningitis | Etiological characterization and diagnosis of parovirus B19 meningitis | Rotbart (1990), Glimaker et al. (1993), Jeffery et al. (1997) |
| Picornaviridae (ss+RNA) | Enterovirus | Aseptic meningitis | Diagnosis of aseptic meningitis (test of choice) | > 90% sensitivity vs. virus isolation | Date et al. (1995) |
| Togaviridae (ss+RNA) | Rubella | Aseptic meningitis, subacute panencephalitis, neonatal infection | Occasional association with encephalitis | Lum et al. (1996), Cam et al. (2001) |
| Flaviviridae (ss+RNA) | Dengue viruses | Encephalitis | Diagnostic potential | Igarachi et al. (1994) |
| | Japanese encephalitis | Encephalitis | Diagnostic potential | Briese et al. (2000), Lanciotti et al. (2000), Lanciotti and Kerst (2001) |
| | West Nile | Encephalitis | Diagnostic potential | Günther (1997), Puchhammer-Stöckl et al. (1995) |
| | Tick borne encephalitis | Encephalitis | Diagnostic potential |  |
Table 2 (Continued)

| Family (nucleic acid) | Virus | Main Common Clinical Syndromes | Significance of NA detection in CSF | Comments | References |
|----------------------|-------|---------------------------------|------------------------------------|----------|------------|
| Bunyaviridae (ss – RNA) | Saint Louis encephalitis | Encephalitis | Diagnostic potential | | Huang et al. (1999b), Lanciotti and Kerst (2001) |
|                      | Jamestown Canyon Encephalitis | Encephalitis | Diagnostic potential | | Huang et al. (1999a,b) |
|                      | La Crosse Aseptic meningitis | Aseptic meningitis | Diagnostic potential | | Huang et al. (1999b) |
|                      | Toscana | | Diagnos of aseptic meningitis | | Valassina et al. (1996, 2000) |
| Ortomyxoviridae (ss – RNA) | Influenza Encephalitis | Encephalitis | Etiological characterization and diagnostic potential in influenza associated CNS disease | | Fujimoto et al. (1998), McCullers et al. (1999), Ito et al. (1999), Togashi et al. (2000) |
| Paramyxoviridae (ss – RNA) | Mumps | Aseptic meningitis | Diagnosis of aseptic meningitis | > 90% sensitivity vs. virus isolation | Poggio et al. (2000) |
|                      | Measles | Acute encephalities, subacute encephalitis, subacute sclerosing panencephalitis (SSPE) | Diagnostic potential in acute encephalitis and SSPE | | Matsuzono et al. (1994), Nakayama et al. (1995), Tomoda et al. (2001) |
|                      | Nipah | Encephalitis | Diagnostic potential | | Paton et al. (1999) |
|                      | Hendra | Meningitis, encephalitis | Diagnostic potential | | O’Sullivan et al. (1997) |
| Arenaviridae (ss – RNA) | Lassa | Encephalitis | Occasional association with encephalities. Etiological characterization of Lassa virus associated encephalopathy? | | Gunther et al. (2001) |
| Rhabdoviridae (ss – RNA) | Rabies | Rabies | Diagnostic potential | | Crepin et al. (1998), Wacharapluesadee and Hemachudha (2001) |
| Retroviridae (RNA, NA) | HTLV-1 | HTLV-associated myelopathy (HAM) | Diagnostic potential | Detection of cell-associated DNA | Kompoliti et al. (1996), Furuya et al. (1998), Cavrois et al. (2000) |

NAAs of other viruses have also been found in the CSF, but without clear association with CNS disease, e.g., hepatitis C virus (HCV), TTV, coronavirus, SV40 (Maggi et al., 1999; Dessau et al., 1999; Cristallo et al., 1997; Maggi et al., 2001; Tognon et al., 2001). HSV-1, herpes simplex virus type 1; HSV-2, herpes simplex virus type 2; VZV, varicella-zoster virus; CMV, cytomegalovirus; EBV, Epstein–Barr virus; HHV-6, human herpesvirus 6; HHV-7, human herpesvirus 7; BKV, BK virus.

<sup>a</sup> dsDNA, double-stranded DNA virus; ssDNA, single-stranded DNA virus; dsRNA, double-stranded RNA virus; ss + RNA positive stranded RNA virus; ss – RNA, negative stranded RNA virus (van Regenmortel et al., 2000).

<sup>b</sup> PCR has been the most commonly employed NA amplification technique.
| Family (nucleic acid) | Virus | Main clinical syndromes | Significance of NA detection in CSF | Comments | References |
|----------------------|-------|-------------------------|-------------------------------------|----------|------------|
| Herpesviridae (dsDNA) | HSV-1 | Subacute encephalitis   | Diagnosis of HSV-associated clinical syndromes in HIV-infected patients | 100% sensitivity, 99% specificity (HIV-infected patients) | Tan et al. (1993), Cinque et al. (1998a) |
| HSV-2 | Subacute encephalitis | Diagnosis of HSV-associated clinical syndromes in HIV-infected patients | 100% sensitivity, 99% specificity (HIV-infected patients) | Miller et al. (1995), Cinque et al. (1998a) |
| VZV | Varicella and herpes zoster (HZ) | Diagnosis of VZV-associated clinical syndromes in HIV-infected patients | Burke et al. (1997), Cinque et al. (1997b), Iten et al. (1999) |
| CMV | Subacute encephalitis, polyradiculopathy | Diagnosis of CMV-associated clinical syndromes in HIV-infected patients | 82–100% sensitivity, 89–100% specificity (HIV-infected patients) | Cinque et al. (1992), Gozlan et al. (1992), Wolf and Spector (1992), Clifford et al. (1993), Fox et al. (1995), Cinque et al. (1998b) |
| EBV | Lymphoproliferative disorders (transplanted patients), PCNSL (HIV-infected patients) | Diagnosis of CMV-associated clinical syndromes in HIV-infected patients | 88–100% sensitivity, 89–100% specificity (PCNSL in HIV-infected patients) | Cinque et al. (1993), Arribas et al. (1995a), de Luca et al. (1995), Cinque et al. (1996b) |
| HHV-6 | Encephalitis (transplanted patients) | Diagnosis of CMV-associated clinical syndromes in HIV-infected patients | 82–100% sensitivity, 89–100% specificity (PCNSL in HIV-infected patients) | Knox et al. (1995), Wang et al. (1999), Bossolasco et al. (1999), Singh and Paterson (2000) |
| Polyomaviridae (dsDNA) | JCV | Progressive multifocal lukoencephalopathy (PML) | Diagnosis (non-invasive test of choice) | 72–100% sensitivity, 92–100% specificity (HIV-infected patients) | Weber et al. (1994), Fong et al. (1995), McGuire et al. (1995), Cinque et al. (1996b), de Luca et al. (1996) |
| BKV | Encephalitis | Occasional association with meningoencephalitis | | Bratt et al. (1999) |

HCV RNA has also been found in the CSF of HIV-infected patients, but without clear association with CNS disease (Maggi et al., 1999; Morsica et al., 1997; Gazzola et al., 2001). PCNSL, primary CNS lymphoma.

a See Table 2, footnotes.
use of these techniques has reduced the time for diagnosis from 4–10 days to 1 day. The diagnostic reliability of both in-house and commercial NA amplification assays has been extensively evaluated, showing a > 90% sensitivity and 48–89% specificity when compared to viral isolation. The low specificity probably reflects enterovirus detection in culture-negative CSF samples from patients with true enterovirus meningitis (Glimaker et al., 1993; Lina et al., 1996; Yerly et al., 1996; Muir and van Loon, 1997; Romero, 1999).

2.2.3. Encephalitis and meningitis caused by zoonotic viruses

Although highly sensitive methods have been developed for detection of viral genomes in patient samples for most of the important arbo- and rodent-borne viruses, these methods are in many cases of limited value in the routine diagnostics. The major reason is that the time period for the viremia is often very short, i.e. the virus is usually no longer detectable at the onset of systemic or CNS disease. A typical example is tick-borne encephalitis (TBE), where attempts to use RT-PCR to tract TBE virus RNA in acute phase CSF or serum have to large extent been unsuccessful, with only a few samples having been found positive in the sero-negative, or in the IgM-positive but IgG-negative, phases (Günther, 1997; Puchhammer-Stöckl et al., 1995; Lundkvist et al., unpublished observation). Other examples where detection of viral genomes is of limited use, and the diagnostics have to be based, or at least supplemented, by serology, are Japanese encephalitis (Igarachi et al., 1994), encephalitis caused by the Western, Eastern and Venezuelan equine encephalitis, and the Dengue viruses. On the other hand, the use of RT-PCR in CSF has rendered more positive results for other flaviviruses, such as West Nile virus, or Bunyaviruses, e.g. La Crosse, Jamestown Canyon or Toscana viruses. Real-time PCR analysis of CSF samples collected from patients with serologically confirmed West Nile encephalitis during the 1999 epidemics in the New York area, revealed a 57% sensitivity and 100% specificity, respectively (Lanciotti et al., 2000). Although a correlation was observed between positivity rate and survival, this observation remains to be confirmed (Briese et al., 2000). Toscana virus, a phlebotomus-transmitted virus causing an endemic infection in the Tuscany area of Italy is the responsible of benign forms of meningitis. By RT-PCR, Toscana virus sequences have been identified in CSF from as many as in 30% of patients with acute meningitis who were hospitalised in this geographic area. These findings not only indicate NA amplification analysis as a valid diagnostic support, but also as a means for estimating the relevance of this disease in the population (Valassina et al., 2000).

2.2.4. HIV-related opportunistic diseases of the CNS

Neurological complications is one of the major problems in patients with HIV infection. Although their frequency has significantly declined in the developed world following the advent of highly active anti-retroviral therapies (HAART), they still represent a major diagnostic and therapeutic challenge. CNS diseases caused by viruses include encephalitis, meningitis, myelitis or mixed pictures caused by herpesviruses, and progressive multi-focal leukoencephalopathy (PML), associated with JCV infection of the CNS. In this field, the impact of diagnostic molecular techniques has been remarkable (Cinque et al., 1997a). Detection of CMV DNA in CSF has shown to be highly sensitive and specific for the diagnosis of CMV encephalitis, a disease reported in as many as one third of AIDS patients (Cinque et al., 1992; Gozlân et al., 1992; Wolf and Spector, 1992; Clifford et al., 1993; Fox et al., 1995; Cinque et al., 1998b). The identification of HSV-1, HSV-2 and varicella-zoster virus DNA in CSF has largely contributed to identify and clinically characterise the CNS complications induced by these viruses, and also provided a useful tool for their diagnosis and clinical management (Tan et al., 1993; Miller et al., 1995; Burke et al., 1997; Cinque et al., 1997a, 1998a; Iten et al., 1999). CSF PCR for JCV has partly replaced the practice of brain biopsy as diagnostic method of choice for PML, though JCV sequences are demonstrated by PCR in only two thirds of the patients, with higher rates of detection in the more advanced stages of disease (Weber et al., 1994; Fong et al., 1995; McGuire et al., 1995;
Furthermore, clearance of JCV DNA from CSF has frequently been observed in patients receiving HAART, in association with PML stabilisation (Miralles et al., 1998; Giudici et al., 2000), suggesting that the rate of JCV DNA detection among PML patients might further decrease as a consequence of anti-HIV therapy. Another virus-related CNS disease in HIV-infected patients is primary CNS lymphoma (PCNSL), which is almost always associated with the presence of EBV in the tumour cells (MacMahon et al., 1991). Studies in patients with histologically proven PCNSL or CNS localization of systemic non-Hodgkin lymphomas have reported a striking association between the presence of these complications and EBV DNA detection in CSF. In some patients, EBV-DNA could even be detected days or months before the lymphoma manifested itself clinically (Cinque et al., 1993; Arribas et al., 1995a; de Luca et al., 1995; Cinque et al., 1996b; Cingolani et al., 2000).

3. Quantitative NA amplification

3.1. Methods

Measuring the amount of NAs in clinical specimens is a successful development of basic diagnostic molecular techniques. Both PCR and other NA amplification techniques have been proven to be reliable for this purpose, and a variety of semi-quantitative and quantitative PCR methods are described (Clementi et al., 1996; Hodinka, 1998; Preiser et al., 2000). Semi-quantitative techniques include methods based on limiting dilution of samples before amplification, or comparison of the extent of amplification between samples and ‘external’ standards at known NA concentration. The main disadvantage of these procedures is that they do not take into account the possible differences in amplification efficiency between the different samples and/or standards. Quantitative techniques allow a more accurate estimate of the NA levels, through co-amplification in the same tube of target NA and an ‘internal’ standard at a known concentration, which enables control of the amplification efficiency.

New automated procedures based on real-time detection of NAs are becoming popular in diagnostic neurovirology. The real-time PCR is based on detection and quantification of a fluorescent reporter. Fluorescence emission is recorded at each cycle making it possible to monitor the PCR reaction during its exponential phase, where the amount of PCR product correlates to the initial quantity of template. Compared to classical methods where the amounts of DNA are measured at the end of amplification, when the amplification efficiency is reduced, real-time PCR is more accurate and expands the dynamic range of quantification. It also eliminates post-PCR processing of amplification products, resulting in reduced risk of contamination and increased speed (Bustin, 2000). There are two general methods for NA quantitation by real-time PCR: those based on the use of DNA-binding dyes, e.g. syber green, or of fluorescence-labelled probes. The latter are employed in the TaqMan (Fig. 3) (Holland et al., 1991; Higuchi et al., 1993; Heid et al., 1996) and LightCycler (Wittwer et al., 1997a,b) technology, that have both been described for quantitation of viral DNA in CSF (Kessler et al., 2000; Verstrepen et al., 2001; Gunther et al., 2001; Nagai et al., 2001; Read et al., 2001; Gautheret-Dejean et al., 2002; Aberle and Puchhammer-Stöckl, 2002) (Table 4). Real-time PCR also allows simultaneous quantification, in the same tube, of different genomes (Read et al., 2001), as well as virus genotyping and mutational analysis.

3.2. Clinical applications

Quantification of viral genomes in the CSF can be important at the time of diagnosis of viral encephalitis or meningitis, in order to obtain diagnostic or prognostic information, as well as for subsequent patient management, e.g. during antiviral therapy. Table 4 summarises the most significant clinical applications of quantitative molecular techniques in viral CNS infections.

CMV and HIV infections of the CNS are good examples where quantitative methods are most useful. In CMV encephalitis, the measurement of
CSF CMV DNA levels at the time of diagnosis is useful in order to distinguish extensive from mild infections (Arribas et al., 1995b; Bestetti et al., 2001). In patients with CMV encephalitis or polyradiculomyelitis, the CMV DNA levels tend to decrease following antiviral therapy with ganciclovir or foscarnet, although the persistence of significant levels is frequent and it is associated with lack of clinical improvement (Cinque et al., 1995; Flood et al., 1997).

Commercial assays, including PCR, NASBA and bDNA assays, have been used for HIV-1 RNA quantification in CSF (Cinque et al., 2000). As a consequence of early virus invasion of the CNS, HIV-1 RNA can be detected in CSF at any stage of HIV infection and irrespective of the presence of neurological symptoms. However, CSF viral load is usually higher in patients with productive HIV infection of brain cells, i.e. HIV-associated dementia or encephalitis (McArthur et al., 1997; Brew et al., 1997; Ellis et al., 1997; Cinque et al., 1998c). Current anti-HIV treatments induce substantial decreases of CSF RNA levels and quantitative molecular techniques can thus be useful to monitor the local response to treatment (Gisslen et al., 1997; Foudraine et al., 1998; Staprans et al., 1999; Gisolf et al., 2000; Price et al., 2001).

4. Post-amplification analyses

4.1. Methods

Besides their use for direct diagnosis, NA amplification techniques constitute the base for genomic analysis. These techniques can yield high amounts of genomic material, which can be analysed for different purposes. These include virus characterisation for epidemiologic and phylogenetic studies, detection of viral mutations, e.g. those associated with antiviral drug resistance, neurotropism or neurovirulence. In addition, genotyping of viruses in CSF may be used to recognise unusual viral strains or to characterise new viral pathogens involved in CNS disease. There are a
| Family          | Virus     | Quantitative techniques employed | Significance of NA quantitation in CSF                                                                 | References                                                                 |
|-----------------|-----------|----------------------------------|--------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------|
| **Herpesviridae** | HSV-1     | Competitive PCR, real-time PCR    | Wide range of level variation (up to $10^7$ copies/ml). Association of high DNA levels with bad HSE outcome? Decline of DNA levels following aciclovir therapy in HSE | Ando et al. (1993), Revello et al. (1997), Domingues et al. (1998), Kessler et al. (2000), Aberle and Puchhammer-Stöckl (2002) |
|                 | HSV-2     | Real-time PCR                     | Narrower range of level variation in patients with HSV-2 meningitis than in patients with HSV-1 encephalitis. Highest levels found in children with congenital infection (up to $10^6$ copies/ml) | Aberle and Puchhammer-Stöckl (2002)                                      |
| **VZV**         |           | Semiquantitative PCR, real-time PCR | Higher levels in patients with herpes zoster complications than in those with varicella                | Puchhammer-Stöckl et al. (1991), Aberle and Puchhammer-Stöckl (2002)    |
| **CMV**         |           | Semiquantitative PCR, competitive PCR, branched DNA | Association of high DNA levels with HIV associated VE or PRP, and with lesion extention in VE Decrease of DNA following antiviral therapy in HIV-infected patients | Arribas et al. (1995b), Cinque et al. (1995), Shinkai and Spector (1995) |
| **EBV**         |           | Real-time PCR                     | Association of high levels with PCNSL or CNS localization of systemic NHL                               | Bossolasco et al. (2002)                                                |
| **HHV-6**       |           | Real-time PCR                     | Low levels (below $10^5$ copies/ml) in children with neurological symptoms. Decrease of DNA levels with antiviral therapy | Aberle and Puchhammer-Stöckl (2002), Gautheret-Dejean et al. (2002)     |
| **Polyomaviridae** | JCV       | Semiquantitative PCR, competitive PCR | Association of high levels with bad prognosis? Clearance or decrease of DNA levels with HAART          | Taoufik et al. (1998), Koralnik et al. (1999), Yiamountos et al. (1999), García de Viedma et al. (1999), Eggers et al. (1999) |
| **Picornaviridae** | Enterovirus | Competitive PCR                   | Not described                                                                                         | Martino et al. (1993), Arola et al. (1996)                                 |
| **Retroviridae** | HIV-I     | Competitive PCR, NAS-BA, branched DNA | Association of high RNA levels with presence and severity of ADC or HIV-E Decrease of RNA levels following antiretroviral therapy | Brew et al. (1997), Ellis et al. (1997), Cinque et al. (1998a), Gisslen et al. (1997), Foudraine et al. (1998), Staprans et al. (1999), Ellis et al. (2000), Gisolf et al. (2000), Price et al. (2001), Nagai et al. (2001) |
|                 | HTLV-1    | Real-time PCR                     | CSF proviral DNA load higher than in blood cells in patients with tropical spastic paraparesis          | Nagai et al. (2001)                                                      |

HSE, herpes simplex encephalitis; VE, ventriculoencephalitis; PRP, polyradiculopathy; PCNSL, primary CNS lymphoma; NHL, non-Hodgkin lymphoma; ADC, AIDS dementia complex; HIV-E, HIV encephalities; PML, progressive multifocal leukoencephalopathy; HAART, highly active antiretroviral therapy.
number of post-amplification methods described, recently reviewed elsewhere (Arens, 1999). Among these, DNA sequencing, restriction fragment length polymorphism (RFLP) and hybridisation-based techniques have all been used in neurovirology.

Nucleotide sequencing is the most accurate method to collect information on genome composition. Automated procedures have been developed during recent years, making sequencing relatively easy to perform (Fig. 4). By RFLP, restriction enzymes are used to digest NAs into fragments of different size, which can be visualised by gel electrophoresis. This technique can be used after CSF PCR with consensus primers to distinguish individual viruses or viral strains (Fig. 2) (Rozenberg and Lebon, 1991; Arthur et al., 1989). Hybridisation-based techniques include classical procedures, such as the Southern Blot, as well as modern high stringency hybridisation. The latter identifies minimal variations in the genome composition, such as single mutations. An example is the reverse hybridisation technique, incorporated into the commercial Line Probe Assay (LIPA), that has been used to detect HIV resistance mutations in CSF and plasma pairs (Cunningham et al., 2000). DNA microarrays, or ‘DNA chip’ technology might become an additional tool for the identification and genomic analysis of virus sequences amplified in the CSF (Pease et al., 1994; Lockhart and Winzeler, 2000; McGlennen, 2001). Despite high costs and current limited availability of technology and instrumentation, the DNA chip technology is in rapid development in virology, especially in the field of research, e.g. for measuring viral gene expression (Chambers et al., 1999; Jenner et al., 2001). Sequences from plasma or other clinical samples have initially been tested for epidemiological or diagnostic purposes, such as screening for multiple HIV-1 drug resistance mutations (Wilson et al., 2000).

4.2. Clinical applications

Table 5 summarises some of the most significant applications of genotypic analysis in neurovirology. The identification of enterovirus strains is an example of virus genotyping for both epidemiological and clinical purposes. Molecular typing of enteroviruses may be useful in epidemiological

![Fig. 4. DNA sequencing from paired CSF and plasma specimens. An example of nucleotide sequencing from paired CSF and plasma samples using cycle-sequencing with dye-labeled oligonucleotides. Amplified products are obtained from paired CSF and plasma specimens following nucleic acid extraction, RNA retrotranscription and PCR amplification of a fragment from the HIV-1 reverse transcriptase (RT) gene. The amplified DNA is purified from unincorporated primers and nucleotides and added to the sequencing reaction mixture. The products of the sequencing reaction are subjected to automated electrophoresis and recognized by a laser scanner. A four-color electropherogram is produced, which is translated into a linear nucleotide sequence by a computer software. The final sequence is compared to reference sequences, e.g., HXB2 for HIV-1. Three nucleotide mutations, resulting in two aminoacid substitutions at codons 215 (treonin → phenylalanin) and 219 (lysin → glutamin) are found in plasma but not in SCF (arrows). Such mutations are associated with resistance to the RT inhibitor drug zidovudine.](image-url)
| Virus family       | Virus        | Genomic region                              | Methods                          | Main findings and significance or post-amplification analysis of CSF                                                                 | References                                                                 |
|-------------------|--------------|---------------------------------------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------|
| Herpesviridae     | HSV-1, HSV-2 | gD                                          | DNA sequencing                   | Possible determinants for neurovirulence not found                                                                             | Rozenberg and Lebon (1996)                                                 |
|                   |              | Tymidine kinase                             | DNA sequencing                   | Possible determinants for neurovirulence not found                                                                             | Lee et al. (1999)                                                          |
| CMV               | UL-97        |                                             | RFLP, DNA sequencing             | Identification of resistance mutations in patients with CMV-induced CNS disease on long-term treatment with ganciclovir         | Wolf et al. (1995)                                                        |
| Adenoviridae      | Adenovirus   | Complete sequence                           | DNA sequencing                   | Identification of a novel neurotropic virus                                                                                       | Cardosa et al. (1999)                                                     |
| Polyomaviridae    | JCV          | VP-1, large T, intergenic region            | RFLP, DNA sequencing, DGGE       | JCV genotyping (genotypes 1–4); association of genotypes 1 and 2 with PML; tracing of human migrations                           | Agostini and Stoner (1995), Sugimoto et al. (1997), Agostini et al. (1997), De Santis and Azzi (2000), Ferrante et al. (2001) |
|                   |              | Hypervariable noncoding transcriptional control (regulatory) region | RFLP, DNA sequencing             | Distinction of archetypal vs. rearranged virus: association of rearranged virus with PML; association of rearranged patterns with bad prognosis of PML? | Agostini and Stoner (1995), Ciappi et al. (1999), Vaz et al. (2000), Pfister et al. (2001), Jensen and Major (2001) |
| BKV               | Regulatory region |                                            | DNA sequencing                   | Distinction of archetypal vs. rearranged virus: association of rearranged virus with BKV-induced meningoencephalitis?               | Stoner et al. (2002)                                                      |
| Picornaviridae    | Enterovirus  | 5' non coding region, other regions         | RFLP, DNA sequencing             | Monitoring EV outbreaks and transmission                                                                                       | Byington et al. (1999), Takami et al. (2000)                               |
|                   |              | 5' non coding region                         | RFLP, DNA sequencing             | Distinction of poliovirus (poliomyelitis) vs. vaccine virus (post-vaccination flaccid paralysis) vs. non polio EV               | Furione et al. (1993), Kammerer et al. (1994), Leparc-Goffart et al. (1996) |
|                   |              | 5' non coding region, VP-1, other regions   | DNA sequencing                   | Potential replacement of traditional subtyping                                                                                 | Oberste et al. (1999), Brown et al. (2000)                                 |
| Paramyxoviridae   | Mumps        | Haemoagglutinin-neuraminidase               | DNA sequencing                   | Identification of a vaccine-strain (Urabe) in association with CNS disease                                                     | Brown et al. (1991), Forsey et al. (1990)                                  |
|                   | Measles      | Nucleocapsid, haemoagglutinin              | DNA sequencing                   | Documentation of evolutionary changes with time                                                                                | Nakayama et al. (1995), Katayama et al. (1997), Kreis and Schoub (1998)   |
|                   | Nipah virus  | Complete genome                             | DNA sequencing                   | Identification of a novel neurotropic virus                                                                                      | Chua et al. (2000)                                                        |
| Flaviviridae      | Yellow fever | Complete genome                             | DNA sequencing                   | Identification of a vaccine-strain (17D) in association with CNS disease                                                       | Martin et al. (2001)                                                      |
| Retroviridae      | HIV          | pol (RT, protease)                          | DNA sequencing, LIPA, DNA microarrays | Identification of different resistance mutations between CSF and blood strains in patients on long-term antiretroviral therapy | Cunningham et al. (2000), Venturi et al. (2000), Cinque et al. (2001), Stingele et al. (2001) |
surveillance programmes, but also has diagnostic and prognostic significance: to correctly identify polioviruses, new enterovirus types or variants, enteroviruses responsible of severe infections, or those causing infections in neonates or immunodeficient (Muir et al., 1998). Molecular typing systems for enteroviruses might become a rapid alternative to traditional serotyping, which is time-consuming, labour-intensive and requires virus isolation in cell culture (Muir et al., 1998; Oberste et al., 1999).

DNA sequencing in the CSF has enabled the diagnosis of CNS diseases caused by attenuate vaccine strains rather than wild-type viruses. Examples are the meningitis cases caused by the Urabe vaccine against mumps in the end of the 80s (Forsey et al., 1990; Brown et al., 1991), or the more recently reported vaccine-induced yellow fever cases (Martin et al., 2001). Novel CNS pathogens have been identified following their isolation and/or amplification in the CSF. Recent examples are the two paramyxoviruses Hendra virus, transmitted by horses and causing meningitis and encephalitis in humans (O’Sullivan et al., 1997), and Nipah virus, identified in patients with encephalitis during the 1998 and 1999 outbreaks in Malaysia and Singapore (Chua et al., 2000). Similarly, a newly described B adeno virus was unexpectedly identified by molecular techniques during the 1997 epidemic of enterovirus 71-associated encephalitis in Malaysia (Cardosa et al., 1999).

Another field of application of post-amplification analyses is pharmacogenomics, a term that indicates the study of genome for treatment management. One of the most significant examples in neurovirology is the study of the HIV genome for mutations selected by anti-HIV drugs (Schinazi et al., 1997; Hirsch et al., 2000). Drug resistant viral mutants can be identified in CSF and these not infrequently show mutation profiles differing from those found in plasma or other body sites (Fig. 4) (Cunningham et al., 2000; Venturi et al., 2000; Cinque et al., 2001; Stingele et al., 2001). These findings might provide information concerning viral dynamics in different body compartments, and might also be useful for clinical management of CNS HIV-induced complications.
5. Practical considerations

It is clear that the use of molecular techniques has tremendously improved the diagnosis and clinical management of viral CNS infections. On the other hand, potential problems related to interpretation of NA amplification results, costs and standardisation of these techniques deserve particular consideration.

5.1. NA amplification in unusual viral CNS diseases

Although the diagnostic value of NA amplification techniques is well established in a number of viral CNS infections such as HSE, enterovirus meningitis or opportunistic diseases in HIV-infected patients, it is still unclear in less frequently encountered infections. Examples are encephalitis caused by certain zoonotic viruses, or complicating viral exanthemas like measles or rubella (Table 2). Viral genomes are occasionally found in the CSF of patients with these infections by PCR or other amplification techniques. However, because of the paucity of cases studied, the rate of detection in diseased patients or controls and their clinical significance are not well known, and the potential of NA amplification methods remains in many cases uncertain.

5.2. Interpretation of NA amplification results

It is not infrequent that viral NAs are found in the CSF in patients with infectious or non-infectious CNS diseases, but without a clear causative association with the disease itself. This is more frequently observed with viruses that may be latent in circulating blood cells, brain or other body sites. An example is the detection of EBV in CSF of patients diagnosed with other CNS infections, such as HSE or HIV-related opportunistic infections (Cinque et al., 1996b; Tang et al., 1997; Studahl et al., 1998; Portolani et al., 1998). Theoretically, this finding might result from sliding of virus or latently infected lymphocytes through an impaired blood-CSF barrier, but also from reactivation of EBV infection in the CNS (Bossolasco et al., 2002). Viral genomes have also been found in the CSF of patients with non-infectious CNS diseases. For instance, both JCV and HHV-6 genomes have been demonstrated in patients with multiple sclerosis, though their etiologic role in this disease has never been confirmed (Ferrante et al., 1998; Liedtke et al., 1995).

In other instances, viral NAs can be detected in CSF prior to the onset of clinically relevant neurological symptoms, which can be advantageous in order to allow for an early diagnosis. This has been observed in AIDS patients, in whom viral agents, e.g. CMV or EBV—not yet causing clinical disease—may occasionally be identified in CSF in patients with another neurological complication (Cinque et al., 1996b).

These examples are the consequence of the extreme sensitivity of NA amplification techniques, and underline the importance of careful interpretation of NA amplification findings in CSF within the individual clinical contexts. It is likely that quantitative molecular techniques might be of help to discriminate a clinically significant infection, characterised by viral replication and high viral loads, from incidental CSF findings.

5.3. Costs and savings of NA amplification techniques

Elevated cost is a potential disadvantage of CSF examination by NA amplification techniques. Taking into account only expenses for technical equipment, reagents, and disposables, the cost per sample of a basic PCR usually varies between approximately 20 and 200 US$ or €. In-house developed assays are the cheapest to perform and costs can be further reduced by avoiding, when possible, expensive procedures for CSF preparation and NA detection, or by using assays for simultaneous examination of multiple viruses. Commercial assays have some advantages, including standardisation and, sometimes, automation (Jungkind, 2001), but are much more expensive. In general, the savings of establishing a rapid diagnosis often overcome the costs of NA amplification techniques (Ross, 1999). In the diagnosis of HSE, the CSF PCR approach is evidently much cheaper than brain biopsy, but it seems cost-effective also when compared to empirical initia-
tiation of antiviral therapy. Using a decision analysis model, the use of CSF PCR was associated with better outcome, and, on the other hand, with significant savings of acyclovir, resulting from higher rate of correct drug discontinuation in PCR-negative patients (Tebas et al., 1998). In aseptic meningitis, cost savings seem to be increased by adopting a PCR testing procedure, as compared to standard practice, especially during the year season characterised by higher enterovirus infection prevalence. Early demonstration of an enterovirus as causative agent is associated with reduced requests for other diagnostic examinations, duration of empirical antibiotic treatments and periods of hospitalisation (Swingler et al., 1994; Rice et al., 1995; Marshall et al., 1997; Ramers et al., 2000).

5.4. Quality control assessment

A major drawback of NA amplification techniques is their limited standardisation. Different protocols are in use for each virus in the different laboratories and reference standards for the evaluation of assay sensitivity are often lacking, making it difficult to compare results among laboratories (Saldanha, 2001). Furthermore, testing of CSF might be subjected to laboratory errors, due to inaccurate test validation, quality of reagents and equipment or staff training (Garrett, 2001). To help obviate these problems, quality control (QC) programmes are being carried out for viruses and other infectious agents. QC assessments for viruses responsible of CNS infections, including enteroviruses, HSV-1, HSV-2 and JCV, have been performed as a part of European Union sponsored QC in virology programmes (van Vliet et al., 1998; Muir et al., 1999; van Loon et al., 1999; Weber et al., 1997; Schloss et al., 2001). These are based on the use of panels consisting of coded samples containing known amounts of NA molecules and control samples, which are distributed to participant laboratories and therein tested blindly. Analysis of reported results has commonly revealed substantial different reports between laboratories, especially with samples containing low amounts of NA. Furthermore, a significant rate of false positive results has been observed (Muir et al., 1999; Schloss et al., 2001). On the other hand, little or no relationship is generally found between performance and the use of in-house rather than commercial techniques.

6. Final remarks

An array of NA amplification techniques is nowadays applicable to the CSF in order to establish an etiological diagnosis of viral infections of the CNS. Over the last 10 years, the spectrum of clinical conditions that can be recognised has largely expanded and diagnostic reliability significantly improved. Quantitative methods have provided a valuable additional tool for clinical management of these diseases, whereas post-amplification techniques have enabled precise characterisation of viral genomes following their recovery in the CSF. Current efforts are aiming at improvement of the diagnostic efficiency of molecular techniques, in both frequent and less common infections. They also will increase the diagnostic speed and standardisation.

References

Abe T, Kobayashi M, Araki K, Kodama H, Fujita Y, Shinozaki T, et al. Infantile convulsions with mild gastroenteritis. Brain Dev 2000;22:301–6.

Aberle SW, Puchhammer-Stöckl E. Diagnosis of herpesvirus infections of the central nervous system. J Clin Virol 2002;25(Suppl):79–85.

Agostini HT, Stoner GL. Amplification of the complete polyomavirus JC genome from brain, cerebrospinal fluid and urine using pre-PCR restriction enzyme digestion. J Neurovirol 1995;1:316–20.

Agostini HT, Yanagihara R, Davis V, Ryschekwitsch CF, Stoner GL. Asian genotypes of JC virus in Native Americans and in a Pacific Island population: markers of viral evolution and human migration. Proc Natl Acad Sci USA 1997;94:14542–6.

Ahmed M, Tashima KT, Caliendo AM, Flanigan TP. Cerebrospinal fluid and plasma HIV-1 RNA stability at 4 degrees C. AIDS 1999;13:1281–2.

Ando Y, Kimura H, Miwata H, Kudo T, Shibata M, Morishima T. Quantitative analysis of herpes simplex virus DNA in cerebrospinal fluid of children with herpes simplex encephalitis. J Med Virol 1993;41:170–3.

Arens M. Methods for subtyping and molecular comparison of human viral genomes. Clin Microbiol Rev 1999;12:612–26.
Arola A, Santti J, Ruuskanen O, Halonen P, Hyypia T. Identification of enteroviruses in clinical specimens by competitive PCR followed by genetic typing using sequence analysis. J Clin Microbiol 1996;34:313–8.

Arribas JR, Clifford DB, Fichtenbaum CJ, Roberts RL, Powderly WG, Storch GA. Detection of Epstein-Barr virus DNA in cerebrospinal fluid for diagnosis of AIDS-related central nervous system lymphoma. J Clin Microbiol 1995a;33:1580–3.

Arribas JR, Clifford DB, Fichtenbaum CJ, Commins DL, Powderly WG, Storch GA. Level of cytomegalovirus (CMV) DNA in cerebrospinal fluid of subjects with AIDS and CMV infection of the central nervous system. J Infect Dis 1995b;172:527–31.

Arribas JR, Storch GA, Clifford DB, Tsolis AC. Cytomegalovirus encephalitis. Ann Int Med 1996;125:577–87.

Arthur RR, Dagnost S, Shah KV. Detection of BK virus and JC virus in urine and brain tissue by the polymerase chain reaction. J Clin Microbiol 1989;27:1174–9.

Aurelius E, Johansson B, Skoldenberg B, Staland A, Forsgren M. Rapid diagnosis of herpes simplex encephalitis by nested polymerase chain reaction assay of cerebrospinal fluid. Lancet 1991;337:189–92.

Aurelius E, Johansson B, Skoldenberg B, Forsgren M. Encephalitis in immunocompetent patients due herpes simplex virus type 1 or 2 as determined by type-specific polymerase chain reaction and antibody assays of cerebrospinal fluid. J Med Virol 1993;39:179–86.

Barah F, Valoley PJ, Chiswick ML, Cleator GM, Kerr JR. Association of human parvovirus B19 infection with acute meningoencephalitis. Lancet 2001;358:729–30.

Baron JM, Rubben A, Grussendorf-Conen EI. Evaluation of a new general primer pair for rapid detection and differentiation of HSV-1, HSV-2, and VZV by polymerase chain reaction. J Med Virol 1996;49:279–82.

Bestetti A, Pierotti C, Terreni M, Zappa A, Vago L, Lazzarin A, et al. Comparison of three nucleic acid amplification assays of cerebrospinal fluid for diagnosis of cytomegalovirus encephalitis. J Clin Microbiol 2001;39:1148–51.

Bossolasco S, Marenzi R, Dahl H, Vago L, Terreni MR, Brococolo F, et al. Human herpesvirus 6 in cerebrospinal fluid of patients infected with HIV: frequency and clinical significance. J Neurol Neurosurg Psychiatry 1999;67:789–92.

Bossolasco S, Cinque P, Ponzoni M, Vigano MG, Lazzarin A, Linde A, et al. Epstein-Barr virus DNA load in cerebrospinal fluid and plasma of patients with AIDS-related lymphoma. J. Neurovirol, 2002.

Bouquillon C, Dewilde A, Andreoletti L, Lambert V, Chieux V, Gerard Y, et al. Simultaneous detection of 6 human herpesviruses in cerebrospinal fluid and aqueous fluid by a single PCR using staur primers. J Med Virol 2000;62:349–53.

Bratt G, Hammarin AL, Grandien M, Hedquist BG, Nenesimo I, Sundelin B, et al. BK virus as the cause of meningoencephalitis, retinitis and nephritis in a patient with AIDS. AIDS 1999;13:1071–5.

Brew BJ, Pemberton L, Cunningham P, Law MG. Levels of human immunodeficiency virus type 1 RNA in cerebrospinal fluid correlate with AIDS dementia stage. J Infect Dis 1997;175:963–6.

Briere T, Glass WG, Lipkin WI. Detection of West Nile virus sequences in cerebrospinal fluid. Lancet 2000;355:1614–5.

Brown BA, Kilpatrick DR, Oberste MS, Pallansch MA. Serotype-specific identification of enterovirus 71 by PCR. J Clin Virol 2000;2:107–12.

Brown EG, Furesz J, Dimock K, Yarosh W, Contreras G. Nucleotide sequence analysis of Urabe mumps vaccine strain that caused meningitis in vaccine recipients. Vaccine 1991;9:840–2.

Burke DG, Kalayjian RC, Vann VR, Madreperla SA, Shick HE, Leonard DG. Polymerase chain reaction detection and clinical significance of varicella-zoster virus in cerebrospinal fluid from human immunodeficiency virus-infected patients. J Infect Dis 1997;167:1080–4.

Bustin SA. Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J Mol Endocrinol 2000;25:169–93.

Byington CL, Taggart EW, Carroll KC, Hillyard DR. A polymerase chain reaction-based epidemiologic investigation of the incidence of nonpolio enteroviral infections in febrile and afebrile infants 90 days and younger. Pediatrics 1999;103:E27.

Cam BV, Fonsmark L, Hue NB, Phuong NT, Poulsen A, Heegaard ED. Prospective case-control study of encephalopathy in children with dengue hemorrhagic fever. Am J Trop Med Hyg 2001;65:848–51.

Cardosa MJ, Krishnan S, Tio PH, Perera D, Wong SC. Isolation of subgenus B adenovirus during a fatal outbreak of enterovirus 71-associated hand, foot, and mouth disease in Sibu, Sarawak. Lancet 1999;354:987–91.

Casas I, Powell L, Klapfer PE, Cleator GM. New method for the extraction of viral RNA and DNA from cerebrospinal fluid for use in the polymerase chain reaction assay. J Virol Methods 1995;53:25–36.

Casas I, Pozo F, Trallerio G, Echevarria JM, Tenorio A. Viral diagnosis of neurological infection by RT multiplex PCR: a search for enterovirus and herpesviruses in a prospective study. J Med Virol 1999;57:145–51.

Caserta MT, Hall CB, Schnabel K, McIntyre K, Long C, Costanzo M, et al. Neuroinvasion and persistence of human herpesvirus 6 in children. J Infect Dis 1994;170:1586–9.

Cassinotti P, Schultz D, Schlageter P, Chevili S, Siegel G. Persistent human parvovirus B19 infection following an acute infection with meningitis in an immunocompetent patient. Eur J Clin Microbiol Infect Dis 1993;12:701–4.

Cassinotti P, Mietz H, Siegel G. Suitability and clinical application of a multiplex nested PCR assay for the diagnosis of herpes simplex virus infections. J Med Virol 1996;50:75–81.

Cavois M, Gessain A, Gout O, Wain-Hobson S, Watte L. Common human T cell leukemia virus type 1 (HTLV-1) integration sites in cerebrospinal fluid and blood lymphocytes of patients with HTLV-1-associated myelopathy/tropical spastic paraesthesia indicate that HTLV-1 crosses
the blood-brain barrier via clonal HTLV-1-infected cells. J Infect Dis 2000;182:1044–50.

Chambers J, Angulo A, Amaratunga D, Guo H, Jiang Y, Wan JS, et al. DNA microarrays of the complex human cytomegalovirus genome: profiling kinetic class with drug sensitivity of viral gene expression. J Virol 1999;73:5757–66.

Chua KB, Bellini WJ, Rota PA, Harcourt BH, Tamin A, Lam SK, et al. Nipah virus: a recently emergent deadly paramyxovirus. Science 2000;288:1432–5.

Ciappi S, Azzi A, De Santis R, Leoncini F, Sterrantino G, Mazzotta F, et al. Archetypal and rearranged sequences of human polyomavirus JC transcription control region in peripheral blood leukocytes and in cerebrospinal fluid. J Gen Virol 1999;80:1017–23.

Cingolani A, Gastaldi R, Fassone L, Pierconti F, Giancola ML, Martini M, et al. Epstein-Barr virus infection is predictive of CNS involvement in systemic AIDS-related non-H Hodgkin's lymphomas. J Clin Oncol 2000;18:3325–30.

Cinque P, Vago L, Brytting M, Castagna A, Accordini V, Sundqvist VA, et al. Cytomegalovirus infection of the central nervous system in patients with AIDS: diagnosis by DNA amplification from cerebrospinal fluid. J Infect Dis 1992;166:1408–11.

Cinque P, Brytting M, Vago L, Castagna A, Parravicini C, Zanchetta N, et al. Epstein-Barr virus DNA in cerebrospinal fluid from patients with AIDS-related primary lymphoma of the central nervous system. Lancet 1993;342:398–401.

Cinque P, Baldanti F, Vago L, Terreni MR, Lillo F, Furione M, et al. Ganciclovir therapy for cytomegalovirus (CMV) infection of the central nervous system in AIDS patients: monitoring by CMV DNA detection in cerebrospinal fluid. J Infect Dis 1995;171:1603–6.

The EU Concerted Action on Virus Meningitis and Encephalitis, Cinque P, Cleator GM, Weber T, Monteyne P, Sindic CJ, van Loon AM. The role of laboratory investigation in the diagnosis and management of patients with suspected herpes simplex encephalitis: a consensus report. J Neurol Neurosurg Psychiatry 1996a;61:339–45.

Cinque P, Vago L, Dahl H, Brytting M, Terreni MR, Fornara C, et al. Polymerase chain reaction on cerebrospinal fluid for diagnosis of virus-associated opportunistic diseases of the central nervous system in HIV-infected patients. AIDS 1996b;10:951–8.

Cinque P, Scarpellini P, Vago L, Linde A, Lazzarin A. Diagnosis of central nervous system complications in HIV-infected patients: cerebrospinal fluid analysis by the polymerase chain reaction. AIDS 1997a;11:1–17.

Cinque P, Bossolasco S, Vago L, Fornara C, Lipari S, Racca S, et al. Varicella-zoster virus (VZV) DNA in cerebrospinal fluid of patients infected with human immunodeficiency virus: VZV disease of the central nervous system or subclinical reactivation of VZV infection? Clin Infect Dis 1997b;25:634–9.

Cinque P, Vago L, Marenzi R, Giudici B, Weber T, Corradini R, et al. Herpes simplex virus infections of the central nervous system in human immunodeficiency virus-infected patients: clinical management by polymerase chain reaction assay of cerebrospinal fluid. Clin Infect Dis 1998a;27:303–9.

European Union Concerted Action on Virus Meningitis and Encephalitis, Cinque P, Cleator GM, Weber T, Monteyne P, Sindic C, Gerna G, et al. Diagnosis and clinical management of neurological disorders caused by cytomegalovirus in AIDS patients. J Neurovirol 1998b;4:120–32.

Cinque P, Vago L, Ceresa D, Mainini F, Terreni MR, Vagani A, et al. Cerebrospinal fluid HIV-1 RNA levels: correlation with HIV encephalitis. AIDS 1998c;12:389–94.

Cinque P, Bestetti A, Morelli P, Presi S. Molecular analysis of cerebrospinal fluid: potential for the study of HIV-1 infection of the central nervous system. J Neurovirol 2000(Suppl 1):S95–S102.

Cinque P, Presi S, Bestetti A, Pierotti C, Racca S, Boeri E, et al. Effect of genotypic resistance on the virological response to highly active antiretroviral therapy in cerebrospinal fluid. AIDS Res Hum Retroviruses 2001;17:377–83.

Clementi M, Menzo S, Bagnarelli P, Valenza A, Paolucci S, Sampaolesi R, et al. Clinical use of quantitative molecular methods in studying human immunodeficiency virus type 1 infection. Clin Microbiol Rev 1996;9:135–47.

Clifford DB, Buller RS, Mohammed S, Robison L, Storch GA. Use of polymerase chain reaction to demonstrate cytomegalovirus DNA in CSF of patients with human immunodeficiency virus infection. Neurology 1993;43:75–9.

Crepin P, Audry L, Rotivel Y, Gacoin A, Caroff C, Bourhy H. Intravitam diagnosis of human rabies by PCR using saliva and cerebrospinal fluid. J Clin Microbiol 1998;36:1117–21.

Cristallo A, Gambaro F, Biamonti G, Ferrante P, Battaglia M, Cereda PM. Human coronavirus polyadenylated RNA sequences in cerebrospinal fluid from multiple sclerosis patients. New Microbiol 1997;20:105–14.

Cunningham PH, Smith DG, Satchell C, Cooper DA, Brew B. Evidence for independent development of resistance to HIV-1 reverse transcriptase inhibitors in the cerebrospinal fluid. AIDS 2000;14:1949–54.

Darin N, Bergstrom T, Fast A, Kyllerman M. Clinical, serological and PCR evidence of cytomegalovirus infection in the central nervous system in infancy and childhood. Neuropediatrics 1994;25:316–22.

Darnell RB. The polymerase chain reaction: application to nervous system disease. Ann Neurol 1993;34:513–23.

Date M, Gondoh M, Kato S, Fukushima M, Nakamoto N, Kobayashi M, et al. A case of rubella encephalitis: rubella virus genome was detected in the cerebrospinal fluid by polymerase chain reaction. No To Hattatsu 1995;27:844–9.

de Luca A, Antinori A, Cingolani A, Larocca LM, Linzalone A, Ammassari A, et al. Evaluation of cerebrospinal fluid EBV-DNA and IL-10 as markers for in vivo diagnosis of AIDS-related primary central nervous system lymphoma. Br J Haematol 1995;90:844–9.

de Luca A, Cingolani A, Linzalone A, Ammassari A, Murri R, Giancola ML, et al. Improved detection of JC virus DNA in cerebrospinal fluid for diagnosis of AIDS-related progres-
Comparison of six commercial DNA extraction kits for recovery of cytomegalovirus DNA from spiked human specimens. J Clin Microbiol 2000;38:3860–3.

Fedele CG, Ciardi M, Delia S, Echevarria JM, Tenorio A. Multiplex polymerase chain reaction for the simultaneous detection and typing of polyomavirus JC, BK and SV40 DNA in clinical samples. J Virol Methods 1999;82:137–44.

Ferrante P, Omodeo-Zorini E, Caldarelli-Stefano R, Mediati M, Fainardi E, Granieri E, et al. Detection of JC virus DNA in cerebrospinal fluid from multiple sclerosis patients. Mult Scler 1998;4:49–54.

Ferrante P, Mediati M, Caldarelli-Stefano R, Lociale L, Mancuso R, Cagni AE, et al. Increased frequency of JC virus type 2 and of dual infection with JC virus type 1 and 2 in Italian progressive multifocal leukoencephalopathy patients. J Neurovirol 2001;7:35–42.

Flood J, Drew WL, Miner R, Jekic-McMullen D, Shen LP, Kolberg J, et al. Diagnosis of cytomegalovirus (CMV) polyradiculopathy and documentation of in vivo anti-CMV activity in cerebrospinal fluid by using branched DNA signal amplification and antigen assays. J Infect Dis 1997;176:348–52.

Fodor PA, Levin MJ, Weinberg A, Sandberg E, Sylman J, Tyler KL. Atypical herpes simplex virus encephalitis diagnosed by PCR amplification of viral DNA from CSF. Neurology 1998;51:554–9.

Fong IW, Britton CB, Luinstra KE, Toma E, Mahony JB. Diagnostic value of detecting JC virus DNA in cerebrospinal fluid of patients with progressive multifocal leukoencephalopathy. J Clin Microbiol 1995;33:484–6.

Fox JD, Han S, Samuelson A, Zhang Y, Neale ML, Westmoreland D. Development and evaluation of nucleic acid sequence based amplification (NASBA) for diagnosis of enterovirus infections using the NucliSens Basic Kit. J Clin Virol 2002;24:117–30.

Forsey T, Mawn JA, Yates PJ, Bentley ML, Minor PD. Differentiation of vaccine and wild mumps viruses using the polymerase chain reaction and dideoxynucleotide sequencing. J Gen Virol 1990;71:987–90.

Fourniaux NA, Hoetelmans RM, Lange JM, de Wolf F, van Benthem BH, Maas JJ, et al. Cerebrospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine. Lancet 1998;351:1547–51.

Fox JD, Brink NS, Zuckerman MA, Neild P, Gazzard BG, Tedder RS, et al. Detection of herpesvirus DNA by nested polymerase chain reaction in cerebrospinal fluid of human immunodeficiency virus-infected persons with neurologic disease: a prospective evaluation. J Infect Dis 1995;172:1087–90.

Fredricks DN, Relman DA. Application of polymerase chain reaction to the diagnosis of infectious diseases. Clin Infect Dis 1999;29:475–86.

Fujimoto S, Kobayashi M, Uemura O, Iwasa M, Ando T, Katoh T, et al. PCR on cerebrospinal fluid to show influenza-associated acute encephalopathy or encephalitis. Lancet 1998;352:873–5.

Furione M, Guillot S, Otelea D, Balanant J, Candrea A, Crainic R. Polioviruses with natural recombinant genomes
isolated from vaccine-associated paralytic poliomyelitis. Virology 1993;196:199–208.

Furuya T, Nakamura T, Goto H, Shirabe S, Nomata K, Kitaoka T, et al. HTLV-1-associated myelopathy associated with multi-organ inflammatory disease: a case report. J Neurol Sci 1998;157:109–12.

Garcia de Viedma D, Alonso R, Miralles P, Berenguer J, Rodriguez-Creixems M, Bouza E. Dual qualitative-quantitative nested PCR for detection of JC virus in cerebrospinal fluid: high potential for evaluation and monitoring of progressive multifocal leukoencephalopathy in AIDS patients receiving highly active antiretroviral therapy. J Clin Microbiol 1999;37:724–8.

Garrett PE. Quality control for nucleic acid tests: common ground and special issues. J Clin Virol 2001;20:15–21.

Gautheret-Dejean A, Manichanh C, Thien-Ah-Koon F, Fillet AM, Mangeney N, Vidaud M, et al. Development of a real-time polymerase chain reaction assay for the diagnosis of human herpesvirus-6 infection and application to bone marrow transplant patients. J Virol Methods 2002;100:27–35.

Gazzola P, Mavilio D, Costa P, Fogli M, Bruzzone B, Icardi G, et al. Possible hepatitis C virus involvement in acute meningoencephalitis/polyradiculitis of HIV-1-co-infected patients. AIDS 2001;15:539–41.

Gisolf EH, Enting RH, Jurriaans S, de Wolf F, van der Ende ME, Hoetelmans RM, et al. Cerebrospinal fluid HIV-1 RNA during treatment with ritonavir/saquinavir or ritonavir/saquinavir/stavudine. AIDS 2000;14:1583–9.

Gisslen M, Norkrans G, Svennerholm B, Hagberg L. The effect on human immunodeficiency virus type 1 RNA levels in cerebrospinal fluid after initiation of zidovudine or didanosine. J Infect Dis 1997;175:434–7.

Guidici B, Vaz B, Bossolasco S, Casari S, Brambilla AM, Luke W, et al. Highly active antiretroviral therapy and progressive multifocal leukoencephalopathy: effects on cerebrospinal fluid markers of JC virus replication and immune response. Clin Infect Dis 2000;30:95–9.

Glimaker M, Johansson B, Oklen P, Ehrnst A, Forsgren M. Detection of enteroviral RNA by polymerase chain reaction in cerebrospinal fluid from patients with aseptic meningitis. Scand J Infect Dis 1993;25:547–57.

Goizan J, Salord JM, Roulet E, Baudrimont M, Caburet F, Picard O, et al. Rapid detection of cytomegalovirus DNA in cerebrospinal fluid of AIDS patients with neurologic disorders. J Infect Dis 1992;166:1416–21.

Günther G. Tick-borne encephalitis-on pathogenesis and prognosis (Thesis). Division of Infectious Diseases. Stockholm, Karolinska Institutte, 1997.

Günther S, Weisner B, Roth A, Grewing T, Asper M, Drosten C, et al. Lassa fever encephalopathy: lassa virus in cerebrospinal fluid but not in serum. J Infect Dis 2001;184:345–9.

Haanpaa M, Dastidar P, Weinberg A, Levin M, Miettinen A, Lapinlampi A, et al. CSF and MRI findings in patients with acute herpes zoster. Neurology 1998;51:1405–11.

Hall CB, Caserta MT, Schnabel KC, Long C, Epstein LG, Insel RA, et al. Persistence of human herpesvirus 6 according to site and variant: possible greater neurotropism of variant A. Clin Infect Dis 1998;26:132–7.

Harris E, Roberts TG, Smith L, Selle J, Kramer LD, Valle S, et al. Typing of dengue viruses in clinical specimens and mosquitoes by single-tube multiplex reverse transcriptase PCR. J Clin Microbiol 1998;36:2634–9.

Heid CA, Stevens J, Livak KJ, Williams PM. Real time quantitative PCR. Genome Res 1996;6:986–94.

Heim A, Schumann J. Development and evaluation of a nucleic acid sequence based amplification (NASBA) protocol for the detection of enterovirus RNA in cerebrospinal fluid samples. J Virol Methods 2002;103:101–7.

Higuchi R, Fockler C, Dollinger G, Watson R. Kinetic PCR analysis: real-time monitoring of DNA amplification reactions. Biotechnology (NY) 1993;11:1026–30.

Hirsch MS, Brun-Vezinet F, D’Aquila RT, Hammer SM, Johnson VA, Kuritzkes DR, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. Jama 2000;283:2417–26.

Hodinka RL. The clinical utility of viral quantitation using molecular methods. Clin Diagn Virol 1998;10:25–47.

Holland PM, Abramson RD, Watson R, Gelfand DH. Detection of specific polymerase chain reaction product by utilizing the 5′-3′ exonuclease activity of Thermus aquaticus DNA polymerase. Proc Natl Acad Sci USA 1991;88:7276–80.

Holodniy M, Mole L, Yen-Lieberman B, Margolis D, Starkey C, Carroll R, et al. Comparative stabilities of quantitative human immunodeficiency virus RNA in plasma from samples collected in VACUTAINER CPT, VACUTAINER PPT, and standard VACUTAINER tubes. J Clin Microbiol 1995;33:1562–6.

Huang C, Campbell W, Grady L, Kirouac I, LaForce FM. Diagnosis of Jamestown Canyon encephalitis by polymerase chain reaction. Clin Infect Dis 1999a;28:1294–7.

Huang C, Chatterjee NK, Grady LJ. Diagnosis of viral infections of the central nervous system. N Engl J Med 1999b;340:483–4.

Igarachi A, Tanaka M, Morita K, Takasu T, Ahmed A, Akram D, et al. Detection of west Nile and Japanese Encephalitis viral genome sequences in cerebrospinal fluid from acute encephalitis cases in Karachi, Pakistan. Microbiol Immunol 1994;38:827–30.

Imai S, Usui N, Sugiuira M, Osato T, Sato T, Tsutsuami H, et al. Epstein-Barr virus genomic sequences and specific antibodies in cerebrospinal fluid in children with neurologic complications of acute and reactivated EBV infections. J Med Virol 1993;40:278–84.

Iten A, Chatelard P, Vuadens P, Miklossy J, Meuli R, Sahli R, et al. Impact of cerebrospinal fluid PCR on the management of HIV-infected patients with varicella-zoster virus infection of the central nervous system. J Neurovirol 1995;5:172–80.

Ito Y, Ichiyama T, Kimura H, Shibata M, Ishiwada N, Kuroki H, et al. Detection of influenza virus RNA by reverse
transcription-PCR and proinflammatory cytokines in influenza-virus-associated encephalopathy. J Med Virol 1999;58:420–5.

Jeffery KJ, Read SJ, Peto TE, Mayon-White RT, Bangham CR. Diagnosis of viral infections of the central nervous system: clinical interpretation of PCR results. Lancet 1997;349:313–7.

Jenner RG, Alba MM, Boshoff C, Kellam P. Kaposi's sarcoma-associated herpesvirus latent and lytic gene expression as revealed by DNA arrays. J Virol 2001;75:891–902.

Jensen PN, Major EO. A classification scheme for human polyomavirus JCV variants based on the nucleotide sequence of the noncoding regulatory region. J Neurovirol 2001;7:280–7.

Johnson G, Nelson S, Petric M, Tellier R. Comprehensive PCR-based assay for detection and species identification of human herpesviruses. J Clin Microbiol 2000;38:3274–9.

Jungkind D. Automation of laboratory testing for infectious diseases using the polymerase chain reaction—our past, our present, our future. J Clin Virol 2001;20:1–6.

Kammerer U, Kunkel B, Korn K. Nested PCR for specific detection and rapid identification of human picornaviruses. J Clin Microbiol 1994;32:285–91.

Katayama Y, Shibahara K, Kohama T, Homma M, Hotta H. Molecular epidemiology and changing distribution of genotypes of measles virus field strains in Japan. J Clin Microbiol 1997;35:2651–3.

Keidan I, Shif I, Keren G, Passwell JH. Rotavirus encephalopathy: evidence of central nervous system involvement during rotavirus infection. Pediatr Infect Dis J 1992;11:773–5.

Kessler HH, Muhlbaumer G, Rinner B, Stelzl E, Berger A, Dorr HW, et al. Detection of Herpes simplex virus DNA by real-time PCR. J Clin Microbiol 2000;38:2638–42.

Keys B, Karis J, Fadeel B, Valentin A, Norkrans G, Hagberg L, et al. V3 sequences of paired HIV-1 isolates from blood and cerebrospinal fluid cluster according to host and show variation related to the clinical stage of disease. Virology 1993;196:475–83.

Kievits T, van Gemen B, van Strijp D, Schukkink R, Dircks M, Adrianaanse H, et al. NASBA isothermal enzymatic in vitro nucleic acid amplification optimized for the diagnosis of HIV-1 infection. J Virol Methods 1991;35:273–86.

Kimberlin DW, Lakeman FD, Arvin AM, Prober CG, Corey L, Powell DA, et al. Application of the polymerase chain reaction to the diagnosis and management of neonatal herpes simplex virus disease. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. J Infect Dis 1995;171:857–63.

Lanciotti RS, Kerst AJ, Nasci RS, Godsey MS, Mitchell CJ, Savage HM, et al. Rapid detection of west nile virus from human clinical specimens, field-collected mosquitoes, and avian samples by a TaqMan reverse transcriptase-PCR assay. J Clin Microbiol 2000;38:4066–71.

Lanciotti RS, Kerst AJ. Nucleic acid sequence-based amplification assays for rapid detection of West Nile and St. Louis encephalitis viruses. J Clin Microbiol 2001;39:4506–13.

Landgren M, Kylleman M, Bergstrom T, Dotevall L, Ljungstrom L, Ricksten A. Diagnosis of Epstein-Barr virus-induced central nervous system infections by DNA amplification from cerebrospinal fluid. Ann Neurol 1994;35:631–5.

Lee JH, Tennessen K, Lilley BG, Unnasch TR. Simultaneous detection of three mosquito-borne encephalitis viruses (eastern equine, La Crosse, and St. Louis) with a single-tube multiplex reverse transcriptase polymerase chain reaction assay. J Am Mosq Control Assoc 2002;18:26–31.

Lee NY, Tang Y, Espy MJ, Kolbert CP, Rys PN, Mitchell PS, et al. Role of genotypic analysis of the thymidine kinase
gene of herpes simplex virus for determination of neurovirulence and resistance to acyclovir. J Clin Microbiol 1999;37:3171–4.

Leparcc-Goffart I, Julien J, Fuchs F, Janatova I, Aymard M, Kopecka H. Evidence of presence of poliovirus genomic sequences in cerebrospinal fluid from patients with post-polio syndrome. J Clin Microbiol 1996;34:2023–6.

Liedtke W, Malessa R, Faustmann PM, Eis-Hubinger AM. Human herpesvirus 6 polymerase chain reaction findings in human immunodeficiency virus associated neurological disease and multiple sclerosis. J Neurovirol 1995;1:253–8.

Lina B, Pozzetto B, Andreoletti L, Beguier E, Bourlet T, Dussaix E, et al. Multicenter evaluation of a commercially available PCR assay for diagnosing enterovirus infection in a panel of cerebrospinal fluid specimens. J Clin Microbiol 1996;34:3002–6.

Linde A, Klapper PE, Monteyne P, Echevarria JM, Cinque P, Rozenberg F, et al. Specific diagnostic methods for herpesvirus infections of the central nervous system: a consensus review by the European Union Concerted Action on Virus Meningitis and Encephalitis. Clin Diagn Virol 1997;8:83–104.

Lockhart DJ, Winzeler EA. Genomics, gene expression and DNA arrays. Nature 2000;405:827–36.

Longo MC, Berninger MS, Hartley JL. Use of uracil DNA glycosylase to control carry-over contamination in polymerase chain reactions. Gene 1990;93:125–8.

Lum LC, Lam SK, Choy YS, George R, Harun F. Dengue encephalitis: a true entity? Am J Trop Med Hyg 1994;50:263–9.

MacMahon EM, Glass JD, Hayward SD, Mann RB, Becker PS, Charache P, et al. Epstein-Barr virus in AIDS-related primary central nervous system lymphoma. Lancet 1991;338:969–73.

Maggi F, Giogri M, Fornai C, Morrica A, Vatteroni ML, Pistello M, et al. Detection and quasispecies analysis of hepatitis C virus in the cerebrospinal fluid of infected patients. J Neurovirol 1999;5:319–23.

Maggi F, Fornai C, Vatteroni ML, Siciliano G, Menichetti F, Tascini C, et al. Low prevalence of TT virus in the cerebrospinal fluid of viremic patients with centra nervous system disorders. J Med Virol 2001;65:418–22.

Markoulatos P, Georgopoulou A, Siafakas N, Plakokefalos E, Tzanakaki G, Kouria-Kremastinou J. Laboratory diagnosis of common herpesvirus infections of the central nervous system by a multiplex PCR assay. J Clin Microbiol 2001;39:4426–32.

Marshall GS, Hauck MA, Buck G, Rabalais GP. Potential cost savings through rapid diagnosis of enteroviral meningitis. Pediatr Infect Dis J 1997;16:1086–7.

Martin M, Tsai TF, Cropp B, Chang GJ, Holmes DA, Tseng J, et al. Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases. Lancet 2001;358:98–104.

Martino TA, Sole MJ, Penn LZ, Liew CC, Liu P. Quantitation of enteroviral RNA by competitive polymerase chain reaction. J Clin Microbiol 1993;31:2634–40.

Matsuzono Y, Narita M, Ishiguro N, Togashi T. Detection of measles virus from clinical samples using the polymerase chain reaction. Arch Pediatr Adolesc Med 1994;148:289–93.

McArthur JC, McClemn DR, Cronin MF, Nance-Sproson TE, Saah AJ, St Clair M, et al. Relationship between human immunodeficiency virus-associated dementia and viral load in cerebrospinal fluid and brain. Ann Neurol 1997;42:689–98.

McCullers JA, Lakeman FD, Whitley RJ. Human herpesvirus 6 is associated with focal encephalitis. Clin Infect Dis 1995;21:571–6.

McCullers JA, Facchini S, Chesney PJ, Webster RG. Influenza B virus encephalitis. Clin Infect Dis 1999;28:898–900.

McGlenenn RC. Miniaturization technologies for molecular diagnostics. Clin Chem 2001;47:393–402.

McGuire D, Barhite S, Hollander H, Miles M. JC virus DNA in cerebrospinal fluid of human immunodeficiency virus-infected patients: predictive value for progressive multifocal leukoencephalopathy. Ann Neurol 1995;37:395–9.

Miller RF, Fox JD, Waite JC, Severn A, Brink NS. Herpes simplex virus type 2 encephalitis and concomitant cytomegalovirus infection in a patient with AIDS: detection of virus-specific DNA in CSF by nested polymerase chain reaction. Genitourin Med 1995;71:262–4.

Minjolle S, Michelet C, Jusselin I, Joannes M, Cartier F, Colimon R. Amplification of the six major human herpesviruses from cerebrospinal fluid by a single PCR. J Clin Microbiol 1999;37:950–3.

Miralles P, Berenguer J, Garcia De Viedma D, Padilla B, Cosin J, Lopez-Bernaldo de Quiros JC, et al. Treatment of AIDS-associated progressive multifocal leukoencephalopathy with highly active antiretroviral therapy. AIDS 1998;12:2467–72.

Morsica G, Bernardi MT, Novati R, Uberti Foppa C, Castagna A, Lazzarin A. Detection of hepatitis C virus genomic sequences in the cerebrospinal fluid of HIV-infected patients. J Med Virol 1997;53:252–4.

Moudgil T, Daar ES. Infectious decay of human immunodeficiency virus type 1 in plasma. J Infect Dis 1993;167:210–2.

Muir P, van Loon AM. Enterovirus infections of the central nervous system. Intervirology 1997;40:153–66.

The European Union Concerted Action on Virus Meningitis and Encephalitis, Muir P, Kammerer U, Korn K, Mulders MN, Poyry T, Weissbrich B, et al. Molecular typing of enteroviruses: current status and future requirements. Clin Microbiol Rev 1998;11:202–27.

Muir P, Ras A, Klapper PE, Cletor GF, Korn K, Aepinus C, et al. Multicenter quality assessment of PCR methods for detection of enteroviruses. J Clin Microbiol 1999;37:1409–14.

Nagai M, Yamano Y, Brennan MB, Mora CA, Jacobson S. Increased HTLV-1 proviral load and preferential expansion of HTLV-1 tax-specific CD8 + T cells in cerebrospinal fluid from patients with HAM/TSP. Ann Neurol 2001;50:807–12.
Nakayama T, Mori T, Yamaguchi S, Sonoda S, Asamura S, Yamashita R, et al. Detection of measles virus genome directly from clinical samples by reverse transcriptase-polymerase chain reaction and genetic variability. Virus Res 1995;35:1–16.

Nishimura S, Ushijima H, Nishimura S, Shiraishi H, Kanazawa C, Abe T, et al. Detection of rotavirus in cerebrospinal fluid and blood of patients with convulsions and gastroenteritis by means of the reverse transcription polymerase chain reaction. Brain Dev 1993;15:457–9.

Oberste MS, Maher K, Pallansch MA. Complete sequence of human parvovirus B19. Arch Dis Child 1993;68:784–5.

O’Sullivan JD, Allworth AM, Paterson DL, Snow TM, Boots R, Gleeson LJ, et al. Fatal encephalitis due to novel paramyxovirus transmitted from horses. Lancet 1997;349:93.

Okumura A, Ichikawa T. Aseptic meningitis caused by human parechovirus. Lancet 1999;354:1253–5.

Puchhammer-Stöckl E, Popow-Kraupp T, Heinz FX, Mandl CW, Kunz C. Establishment of PCR for the early diagnosis of herpes simplex encephalitis. J Med Virol 1990;32:77–82.

Quereda C, Corral I, Laguna F, Valencia ME, Tenorio A, Echeverria JE, et al. Diagnostic utility of a multiplex herpesvirus PCR assay performed with cerebrospinal fluid from human immunodeficiency virus-infected patients with neurological disorders. J Clin Microbiol 2000;38:3061–7.

Read SJ, Kurtz JB. Laboratory diagnosis of common viral infections of the central nervous system by using a single multiplex PCR screening assay. J Clin Microbiol 1999;37:1352–5.

Revelo MG, Baldanti F, Sarasini A, Zella D, Zavattoni M, Gerna G. Quantitation of herpes simplex virus DNA in cerebrospinal fluid of patients with herpes simplex encephalitis by the polymerase chain reaction. J Virol 1997;71:183–91.

Rice SK, Heinl RE, Thornton LL, Opal SM. Clinical characteristics, management strategies, and cost implications of a statewide outbreak of enterovirus meningitis. Clin Infect Dis 1995;20:931–7.

Roberts TC, Storch GA. Multiplex PCR for diagnosis of AIDS-related central nervous system lymphoma and toxoplasmosis. J Clin Microbiol 1997;35:268–9.

Romero JR. Reverse-transcription polymerase chain reaction detection of the enteroviruses. Arch Pathol Lab Med 1999;123:1161–9.
Ross JS. Financial determinants of outcomes in molecular testing. Arch Pathol Lab Med 1999;123:1071–5.
Rotbart HA, Levin MJ, Villarreal LP, Tracy SM, Semler BL, Wimmer E. Factors affecting the detection of enteroviruses in cerebrospinal fluid with coxsackievirus B3 and poliovirus 1 cDNA probes. J Clin Microbiol 1985;22:220–4.
Rotbart HA. Diagnosis of enteroviral meningitis with the polymerase chain reaction. J Pediatr 1990;117:85–9.
Rotbart HA, Sawyer MH, Fast S, Lewinski C, Murphy N, Keyser EF, et al. Diagnosis of enteroviral meningitis by using PCR with a colorimetric microwell detection assay. J Clin Microbiol 1994;32:2590–2.
Rozenberg F, Lebon P. Amplification and characterization of herpesvirus DNA in cerebrospinal fluid from patients with acute encephalitis. J Clin Microbiol 1991;29:2412–7.
Rozenberg F, Lebon P. Analysis of herpes simplex virus type 1 glycoprotein D nucleotide sequence in human herpes simplex encephalitis. J Neurovirol 1996;2:289–95.
Rubin SJ. Detection of viruses in spinal fluid. Am J Med 1983;75:124–8.
Saldanha J. Validation and standardization of nucleic acid amplification technology (NAT) assays for the detection of viral contamination of blood and blood products. J Clin Virol 2001;20:7–13.
Scaramozzino N, Crane JM, Jouan A, DeBriel DA, Stoll F, Garin D. Comparison of flavivirus universal primer pairs and development of a rapid, highly sensitive heminested reverse transcription-PCR assay for detection of flaviviruses targeted to a conserved region of the NS5 gene sequences. J Clin Microbiol 2001;39:1922–7.
Schinazi RF, Larder BA, Mellors JW. Resistance table: mutations in retroviral genes associated with drug resistance. Int Antiviral News 1997;5:129–42.
Schlesinger Y, Buller RS, Brunstrom JE, Moran CJ, Storch GA. Expanded spectrum of herpes simplex encephalitis in childhood. J Pediatr 1995a;126:234–41.
Schlesinger Y, Tebas P, Gaudreault-Keener M, Buller RS, Storch GA. Herpes simplex virus type 2 meningitis in the absence of genital lesions: improved recognition with use of the polymerase chain reaction. Clin Infect Dis 1995b;20:842–8.
Schloss L, Linde A, Falk KI, Cinque P, Klapper P, Popow-Kraupp T, et al. European panels for quality control of nucleic acid amplification of herpes simplex virus (HSV). Fifth Annual Meeting of the European Society for Clinical Virology, Lathli, Finland; 2001.
Shepard RN, Schock J, Robertson K, Shugars DC, Dyer J, Vernazza P, et al. Quantitation of human immunodeficiency virus type 1 RNA in different biological compartments. J Clin Microbiol 2000;38:1414–8.
Shinkai M, Spector SA. Quantitation of human cytomegalovirus (HCMV) DNA in cerebrospinal fluid by competitive PCR in AIDS patients with different HCMV central nervous system diseases. Scand J Infect Dis 1995;27:559–61.
Singh N, Paterson DL. Encephalitis caused by human herpesvirus-6 in transplant recipients: relevance of a novel neurotropic virus. Transplantation 2000;69:2474–9.
Staprans S, Marlone N, Glidden D, Novakovic-Agopian T, Grant RM, Heyes M, et al. Time course of cerebrospinal fluid responses to antiretroviral therapy: evidence for variable compartmentalization of infection. AIDS 1999;13:1051–61.
Steuler H, Storch-Hagenlocher B, Wildemann B. Distinct populations of human immunodeficiency virus type 1 in blood and cerebrospinal fluid. AIDS Res Hum Retroviruses 1992;8:53–9.
Stingele K, Haas J, Zimmermann T, Stingle R, Hubsch-Muller C, Freitag M, et al. Independent HIV replication in paired CSF and blood viral isolates during antiretroviral therapy. Neurology 2001;56:355–61.
Stoner GL, Alappan R, Jobes DV, Ryschkewitsch CF, Landry ML. BK virus regulatory region rearrangements in brain and cerebrospinal fluid from a leukemia patient with tubulointerstitial nephritis and meningoencephalitis. Am J Kidney Dis 2002;39:1102–12.
Studahl M, Bergstrom T, Ekeland-Sjoberg K, Ricksten A. Detection of cytomegalovirus DNA in cerebrospinal fluid in immunocompetent patients as a sign of active infection. J Med Virol 1995;46:274–80.
Studahl M, Bergstrom T, Hagberg L. Acute viral encephalitis in adults—a prospective study. Scand J Infect Dis 1998;30:215–20.
Suga S, Yoshikawa T, Asano Y, Kozawa T, Nakashima T, Kobayashi I, et al. Clinical and virological analyses of 21 infants with exanthem subitum (roseola infantum) and central nervous system complications. Ann Neurol 1993;33:597–603.
Sugimoto C, Kitamura T, Guo J, Al-Ahdal MN, Shchelkunov SN, Otowa B, et al. Typing of urinary JC virus DNA offers a novel means of tracing human migrations. Proc Natl Acad Sci USA 1997;94:9191–6.
Swingler G, Delport S, Hussey G. An audit of the use of antibiotics in presumed viral meningitis in children. Pediatr Infect Dis J 1994;13:1107–10.
Takami T, Sonodat S, Houyou H, Kawashima H, Takei Y, Miyajima T, et al. Diagnosis of horizontal enterovirus infections in neonates by nested PCR and direct sequence analysis. J Hosp Infect 2000;45:283–7.
Tan SV, Guiloff RJ, Scaravilli F, Klapper PE, Cleator GM, Gazzard BG. Herpes simplex type 1 encephalitis in acquired immunodeficiency syndrome. Ann Neurol 1993;34:619–22.
Tang YW, Epsy MJ, Persing DH, Smith TF. Molecular evidence and clinical significance of herpesvirus coinfection in the central nervous system. J Clin Microbiol 1997;35:2869–72.
Tang YW, Persing DH. Molecular detection and identification of microorganisms. In: Murray PR, Pfaller MA, Tenover FC, Yolken RH, editors. Manual of clinical microbiology. Washington, DC: American Society for Microbiology, 1999:215–44.
Tang YW, Mitchell PS, Espy MJ, Smith TF, Persing DH. Molecular diagnosis of herpes simplex virus infections in the central nervous system. J Clin Microbiol 1999;37:2127–36.
Taoufik Y, Gasnault J, Karaterki A, Pierre Ferey M, Marchadier E, Goujard C, et al. Prognostic value of JC virus load in cerebrospinal fluid of patients with progressive multifocal leukoencephalopathy. J Infect Dis 1999;180:1816–20.

Tebas P, Nease RF, Storch GA. Use of the polymerase chain reaction in the diagnosis of herpes simplex encephalitis: a decision analysis model. Am J Med 1998;105:287–95.

Tedder DG, Ashley R, Tyler KL, Levin MJ. Herpes simplex virus infection as a cause of benign recurrent lymphocytic meningitis. Ann Intern Med 1994;121:334–8.

Tenorio A, Echevarria JE, Casas I, Echevarria JM, Tabares E. Detection and typing of human herpesviruses by multiplex polymerase chain reaction. J Virol Methods 1993;44:261–9.

Togashi T, Matsuzono Y, Narita M. Epidemiology of influenza-associated encephalitis-encephalopathy in Hokkaido, the northernmost island of Japan. Pediatr Int 2000;42:192–6.

Tognon M, Martin F, Iaccheri L, Cultrera R, Contini C. Investigation of the simian polyomavirus SV40 as a potential causative agent of human neurological disorders in AIDS patients. J Med Microbiol 2001;50:165–72.

Tomoda A, Shiraishi S, Hosoya M, Hamada A, Miike T. Combined treatment with interferon-alpha and ribavirin for subacute sclerosing panencephalitis. Pediatr Neurol 2001;24:54–9.

Torigoe S, Koide W, Yamada M, Miyashiro E, Tanaka-Taya K, Yamanishi K. Human herpesvirus 7 infection associated with central nervous system manifestations. J Pediatr 1996;129:301–5.

Troendle Atkins J, Demmler GJ, Williamson WD, McDonald JM, Istaas AS, Buffone GJ. Polymerase chain reaction to detect cytomegalovirus DNA in the cerebrospinal fluid of neonates with congenital infection. J Infect Dis 1994;169:1334–7.

Tyler KL. Polymerase chain reaction and the diagnosis of viral central nervous system diseases. Ann Neurol 1994;36:809–11.

Urdea MS. Branched DNA signal amplification. Biotechnology (NY) 1994;12:926–8.

Ushijima H, Xin QK, Nishimura S, Morikawa S, Abe T. Detection and sequencing of rotavirus VP7 gene from human materials (stools, sera, cerebrospinal fluids, and throat swabs) by reverse transcription and PCR. J Clin Microbiol 1994;32:2893–7.

Valassina M, Cusi MG, Valensi PE. Rapid identification of Toscana virus by nested PCR during an outbreak in the Siena area of Italy. J Clin Microbiol 1996;34:2500–2.

Valassina M, Meacci F, Valensi PE, Cusi MG. Detection of neurotropic viruses circulating in Tuscany the incise role of Toscana virus. J Med Virol 2000;60:86–90.

van den Berg JS, van Zeijl JH, Rotteveel JJ, Melchers WJ, Gabreels FJ, Galama JM. Neuroinvasion by human herpesvirus type 7 in a case of exanthem subitum with severe neurologic manifestations. Neurology 1999;52:1077–9.

European Union Concerted Action on Virus Meningitis and Encephalitis, van Loon AM, Cleator GC, Ras A. External quality assessment of enterovirus detection and typing. Bull World Health Org 1999;77:217–23.

van Regenmortel MHV, Fauquet CM, Bishop DHL, Carstens EB, Estes MK, Lemon SM, et al. In: Virus Taxonomy. The classification and nomenclature of viruses. The seventh report of the international committee on taxonomy of viruses. Academic Press, San Diego; 2000, p. 1167.

The European Union Concerted Action on Viral Meningitis and Encephalitis, van Vliet KE, Glimaker M, Leben P, Klapper PE, Taylor CE, Ciardi M, et al. Multicenter evaluation of the AmpliCor Enterovirus PCR test with cerebrospinal fluid from patients with aseptic meningitis. J Clin Microbiol 1998;36:2652–7.

Vaz B, Cinque P, Pickhardt M, Weber T. Analysis of the transcriptional control region in progressive multifocal leukoencephalopathy. J Neurovirol 2000;6:398–409.

Venturi G, Catucci M, Romano L, Corsi P, Leoncini F, Valensi PE, et al. Antiretroviral resistance mutations in human immunodeficiency virus type 1 reverse transcriptase and protease from paired cerebrospinal fluid and plasma samples. J Infect Dis 2000;181:740–5.

Verstrepen WA, Kuhn S, Kockx MM, Van De Vyvere ME, Mertens AH. Rapid detection of enterovirus RNA in cerebrospinal fluid specimens with a novel single-tube real-time reverse transcription-PCR assay. J Clin Microbiol 2001;39:4093–6.

Voltz R, Jager G, Seelos K, Fuhrly L, Hohlfeld R. BK virus encephalitis in an immunocompetent patient. Arch Neurol 1996;53:101–3.

Wacharapluesadee S, Hemachudha T. Nucleic-acid sequence based amplification in the rapid diagnosis of rabies. Lancet 2001;358:892–3.

Wang FZ, Linde A, Hagglund H, Testa M, Locasciulli A, Voltz R, Jager G, Seelos K, Fuhrly L, Hohlfeld R. BK virus encephalitis in an immunocompetent patient. Arch Neurol 1996;53:101–3.

Wacharapluesadee S, Hemachudha T. Nucleic-acid sequence based amplification in the rapid diagnosis of rabies. Lancet 2001;358:892–3.

Wang FZ, Linde A, Hagglund H, Testa M, Locasciulli A, Ljungman P. Human herpesvirus 6 DNA in cerebrospinal fluid specimens from allogeneic bone marrow transplant patients: does it have clinical significance? Clin Infect Dis 1999;28:562–8.

Weber T, Turner RW, Frye S, Ruf B, Haas J, Schielke E, et al. Specific diagnosis of progressive multifocal leukoencephalopathy by polymerase chain reaction. J Infect Dis 1994;169:1138–41.

Weber T, Frye S, Bodemer M, Otto M, Luke W. Clinical implications of nucleic acid amplification methods for the diagnosis of viral infections of the nervous system. J Neurovirol 1996;2:175–90.

European Union Concerted Action on Virus Meningitis and Encephalitis, Weber T, Klapper PE, Cleator GM, Bodemer M, Luke W, Knowles W, et al. Polymerase chain reaction for detection of JC virus DNA in cerebrospinal fluid: a quality control study. J Virol Methods 1997;69:231–7.

Wiedbrauk DL, Cunningham W. Stability of herpes simplex virus DNA in cerebrospinal fluid specimens. Diagn Mol Pathol 1996;5:249–52.

Wilson JW, Bean P, Robins T, Graziano F, Persing DH. Comparative evaluation of three human immunodeficiency virus genotyping systems: the HIV-GenotypR method, the
HIV PRT GeneChip assay, and the HIV-1 RT line probe assay. J Clin Microbiol 2000;38:3022–8.

Wittwer CT, Herrmann MG, Moss AA, Rasmussen RP. Continuous fluorescence monitoring of rapid cycle DNA amplification. Biotechniques 1997; 22: 130–131, 134–138.

Wittwer CT, Ririe KM, Andrew RV, David DA, Gundry RA, Balis UJ. The LightCycler: a microvolume multisample fluorimeter with rapid temperature control. Biotechniques 1997b;22:176–81.

Wolf DG, Spector SA. Diagnosis of human cytomegalovirus central nervous system disease in AIDS patients by DNA amplification from cerebrospinal fluid. J Infect Dis 1992;166:1412–5.

Wolf DG, Lee DJ, Spector SA. Detection of human cytomegalovirus mutations associated with ganciclovir resistance in cerebrospinal fluid of AIDS patients with central nervous system disease. Antimicrob Agents Chemother 1995;39:2552–4.

Yerly S, Gervaix A, Simonet V, Callisch M, Perrin L, Wunderli W. Rapid and sensitive detection of enteroviruses in specimens from patients with aseptic meningitis. J Clin Microbiol 1996;34:199–201.

Yiannoutsos CT, Major EO, Curfman B, Jensen PN, Gravell M, Hou J, et al. Relation of JC virus DNA in the cerebrospinal fluid to survival in acquired immunodeficiency syndrome patients with biopsy-proven progressive multifocal leukoencephalopathy. Ann Neurol 1999;45:816–21.

Yoshikawa T, Ihira M, Suzuki K, Suga S, Matsubara T, Furukawa S, et al. Invasion by human herpesvirus 6 and human herpesvirus 7 of the central nervous system in patients with neurological signs and symptoms. Arch Dis Child 2000;83:170–1.

Zhang F, Tetali S, Wang XP, Kaplan MH, Cromme FV, Ginocchio CC. Detection of human cytomegalovirus pp67 late gene transcripts in cerebrospinal fluid of human immunodeficiency virus type 1-infected patients by nucleic acid sequence-based amplification. J Clin Microbiol 2000;38:1920–5.